Top

News & Events

Archive: 2015

News Archive

Avita Medical sells Respiratory Business for $2.64m

Northridge, CA, USA and Cambridge, United Kingdom — Avita Medical Ltd. (ASX: AVH), (OTCQX: AVMXY), a regenerative medicine company specializing in the treatment of wounds and skin defects, today announced that it has signed an agreement to sell its respiratory business to Medical Developments International (ASX: MVP) for $2.64m.

Read more »

Abcodia’s ROCA Test® used in UKCTOCS trial; data shows ovarian cancer screening could reduce mortality by 20%

Data published in The Lancet

Read more »

Ablynx Completes Enrolment Of The First-In-Infant Phase I/IIa Safety Study With Its Anti-RSV Nanobody And Extends The Trial For Younger Infants

Ghent, Belgium,  – Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced that it has completed target enrolment of the first-in-infant Phase I/IIa safety study with its anti-RSV Nanobody, ALX-0171, and is on track to publish top line results in the first half of 2016. ALX-0171 is a wholly-owned Nanobody drug candidate, administered through inhalation, for the treatment of respiratory syncytial virus (RSV) infection in infants.

Read more »

Dimerix Limited announces appointment of Dr Liz Jazwinska as Non-Executive Director

Melbourne AUSTRALIA: Dimerix Limited (ASX: DXB) is pleased to announce the appointment of Dr Liz Jazwinska as Non-Executive Director.

Read more »

William (Bill) Hunter MD to Join Adherium Board

Melbourne, Australia - Adherium Limited (ASX: ADR), a global leader in digital health technologies addressing sub‐optimal medication use in chronic disease, today confirmed that Canadabased pharmaceutical entrepreneur William (Bill) Hunter MD has agreed to join the Adherium Board as a non‐executive director.

Read more »

BeiGene selects GE’s FlexFactory™ biomanufacturing platform for pilot cGMP production facility in China

CHALFONT ST. GILES, UK and BEIJING, CHINA – GE Healthcare’s Life Sciences business and BeiGene, Ltd. today announced that BeiGene has selected GE’s FlexFactory™ biomanufacturing platform for its first current Good Manufacturing Practices (cGMP) biomanufacturing facility in Suzhou, China. Currently under construction, the facility is expected to be operational by 2017.

Read more »

NetScientific appoints diagnostics leader Lawrence Cohen as CEO of Glycotest Inc.

London, UK – NetScientific plc (AIM: NSCI, “NetScientific” or the “Group”), the transatlantic biomedical and healthcare technology group, today announces the appointment of Lawrence ‘Larry’ Cohen as CEO of its portfolio company, Glycotest, effective from 4 January 2016.

Read more »

Dutch VC Aglaia BioMedical Ventures invests in Swiss biotech Inthera Bioscience

Bilthoven, The Netherlands – Dutch Aglaia BioMedical Ventures today announces its investment in Swiss biopharmaceutical company Inthera Bioscience. Inthera Bioscience focuses on the development of first-in-class targeted small molecule therapies for solid tumors. The $3.7 million (EUR 3.4 million) financing round was led by MS Ventures, with equal contribution from Aglaia Oncology Fund II and Danish Novo Seeds. EVA Basel also participated in the financing. This is the second investment of the new Aglaia Oncology Fund after last month’s investment in Dutch based InteRNA Technologies.

Read more »

Avita Medical: FDA Grants ReCell Expedited Access Pathway Designation

Northridge, CA, USA and Cambridge, United Kingdom - Avita Medical Ltd. (ASX: AVH), (OTCQX: AVMXY), a regenerative medicine company specializing in the treatment of wounds and skin defects, today announced that the US FDA has ruled that the ReCell® Autologous Cell Harvesting Device is eligible for earlier regulatory approval for burns treatment in the United States.

Read more »

NETSCIENTIFIC: Ex Novartis Diagnostics president, Gene Walther is appointed CEO of Vortex BioSciences and NetScientific’s Head of Diagnostics

London, UK – NetScientific plc (AIM: NSCI, ‘NetScientific’ or the ‘Group’), the transatlantic biomedical and healthcare technology group, continues its restructuring towards a sector franchise model with the appointment of Gene Walther. Gene will become CEO of the Group’s portfolio company, Vortex BioSciences (‘Vortex’), and head of NetScientific’s diagnostics franchise, of which Vortex is the key asset.

Read more »

Premaitha Health signs Investment Agreement with Thermo Fisher Scientific

Manchester, UK – Premaitha Health PLC (AIM: NIPT, “Premaitha” or the “Company”) signs an agreement for Thermo Fisher Scientific to provide a £5 million investment in Premaitha.
Premaitha’s CE-marked, non-invasive prenatal screening (NIPT) product, the IONA® test, runs on Thermo Fisher’s two sequencing instruments, the Ion Proton and Ion Chef. Thermo Fisher is the world leader in serving science, with revenues of $17 billion and approximately 50,000 employees in 50 countries.

Read more »

Premaitha Health plc: Results for the half year ended 30 September 2015

Manchester, UK – Premaitha Health PLC (AIM: NIPT, “Premaitha” or the “Company”) announces its results for the half year ended 30 September 2015.

Read more »

Dimerix Limited receives Orphan Designation for its lead drug candidate targeting patients with chronic kidney disease

Melbourne, Australia - Dimerix Limited (ASX: DXB) today announced it had received Orphan Designation from the United States Food and Drug Administration (FDA) for propagermanium and irbesartan, the constituent parts of its drug candidate DMX-200 for the treatment of a condition known as focal segmental glomerulosclerosis (FSGS), a leading cause of chronic kidney disease, which is a serious medical condition.

Read more »

SEVENTURE: A Major Pharmaceutical Company participates as Strategic investor in Health for Life Capital™ the first investment vehicle focused on the microbiome health and nutrition revolutionary sector

Paris, France – Seventure Partners, a European leader in financing innovation, today announced the completion of a new closing for Health for Life Capital ™, the first investment vehicle in the world to anticipate the microbiome revolution in the fields of health and nutrition, with Novartis Pharma AG agreeing to participate. This closing will increase the total amount of funds available to €160Mio.

Read more »

ImmBio Initiates First-in-Human Studies of its Novel Pneumococcal Vaccine, PnuBioVax

Cambridge, UK — ImmunoBiology Ltd (“ImmBio” or the Company), a biopharmaceutical company developing next generation anti-infective vaccines based on its proprietary ImmBioVax™ technology, today announces that it has initiated enrolment for a First-in-Human study of its novel vaccine (“PnuBioVax™”) against the bacterial pathogen Streptococcus pneumoniae.

Read more »

Karus Therapeutics Announces Strategic Collaboration with The University of Texas MD Anderson Cancer Center

Oxford, UK – Karus Therapeutics (‘Karus’), a leader in the development of innovative medicines with breakthrough potential in the treatment of hematological cancers and solid tumor immunotherapy, today announced that it has entered into a strategic pre-clinical and clinical collaboration with The University of Texas MD Anderson Cancer Center. The collaboration will include both of Karus’s lead cancer candidates, KA2237 and KA2507.

Read more »

Oxford Gene Technology Announces Commercial and Financial Highlights for FY 2015

Oxford and Cambridge, UK – Oxford Gene Technology (OGT), the molecular genetics company, has continued its impressive sales performance and has refocused its business to take advantage of the significant growth potential in the global genomics market. Commercial and financial highlights for the year ended 30 September show the company delivering £14.3m sales revenues on the continuing products business (FY2014: £9.7m, up 47%).

Read more »

Avita Medical Highlights Report of 63% Decreased Length of Hospital Stay for Patients with Large Burns treated using ReCell®

Findings presented at ABA Southern Region Burn Conference

Read more »

ADC Therapeutics Announces Positive Pre-clinical Results for Two of its Novel ADCs at the American Society of Hematology Conference

Lausanne, Switzerland, London, UK and Murray Hill, New Jersey, US – ADC Therapeutics (ADCT), the oncology drug development company, today presented pre-clinical results for both ADCT-301 and ADCT-402, its novel Antibody Drug Conjugates (ADCs) in hematological tumours at the 57th American Society of Hematology (ASH) Annual Meeting, December 5-8, in Orlando, Florida.  ADCT-301 is currently in Phase I for lymphoma and leukemia. Yesterday ADCT announced that it has received IND clearance from the FDA to begin two Phase I clinical trials with ADCT-402 in hematological tumors.

Read more »

DNAe Expands US Operations with Clinical Diagnostic Development and Manufacturing Site in San Diego

London, UK and Albuquerque, NM, USA – DNA Electronics (‘DNAe’), the inventors of semiconductor DNA sequencing technology and developers of a new, revolutionary point-of-need test for bloodstream infections, will expand and relocate its US operations from Albuquerque, NM to San Diego, CA. The move is expected to be completed by the end of 2016.

Read more »

ADC Therapeutics Receives FDA Clearance to Begin Clinical Studies for its Second Novel Antibody Drug Conjugate ADCT-402 against Lymphomas and Leukemia

Lausanne, Switzerland, London, UK and Murray Hill, New Jersey, US – ADC Therapeutics SA (ADCT or the “Company”), the oncology drug development company focused on Antibody Drug Conjugates (ADCs), today announced that it has received clearance from the US Food and Drug Administration (FDA) to begin clinical trials with ADCT-402, a novel antibody drug conjugate targeting CD19, a cell-surface antigen, which is over-expressed in many patients with B-cell non-Hodgkin Lymphoma (NHL) and B-cell Acute Lymphoblastic Leukemia (ALL). ADCT plans to initiate Phase I clinical trials in both NHL and ALL.

Read more »

GE Healthcare Life Sciences strengthens business resilience with ISO 22301 business continuity accreditation for chromatography media

CHALFONT ST. GILES, UK – GE Healthcare’s Life Sciences business today announced that its chromatography media manufacturing facility and supporting functions in Uppsala, Sweden have been certified to ISO 22301, the international standard for business continuity management systems. Chromatography medium is a key component in the production of biopharmaceuticals such as insulin and monoclonal antibodies – vital medicines which help save the lives of millions of people. The complex nature of biopharmaceuticals makes manufacturing a challenge, in which a consistent high-quality end product is dependent on the use of equally consistent, high-quality key manufacturing components. GE Healthcare Life Sciences has taken extensive actions to help secure a continuous supply of media to the biopharmaceutical industry,  and the achievement of ISO 22301 accreditation provides further assurance that the company has a robust program in place to maintain business continuity, even under the most unforeseen and challenging conditions.

Read more »

Clinigen Group Partners with Sunesis to Initiate a Compassionate Use Program for Patients with Relapsed or Refractory Acute Myeloid Leukemia

Burton-on-Trent, UK - Clinigen Group plc’s (AIM: CLIN, ‘Clinigen’ or the ‘Group’) Managed Access (MA) division has partnered with Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) to manage its compassionate use program for vosaroxin. The program has been initiated today and will be made available to eligible patients in the U.S. and selected European countries diagnosed with relapsed or refractory acute myeloid leukemia (AML).

Read more »

ProAxsis' ProteaseTag™ technology shown to effectively monitor patients with chronic obstructive pulmonary disease

London, UK – Further to the announcement on 30 November 2015, NetScientific plc’s (AIM: NSCI, “NetScientific” or the “Group”) portfolio company, ProAxsis, a medical diagnostics spin-out from Queen’s University Belfast, will present new data today which validates the use of ProAxsis’ ProteaseTag™ Active Neutrophil Elastase (NE) Immunoassay in the monitoring of patients with chronic obstructive pulmonary disease (COPD) for the first time.

Read more »

Histide Announces Publication in Nature Materials Revealing Mechanisms Governing Stem Cell Differentiation

Schindellegi, Switzerland - Histide AG, a biotech intellectual property platform company focused on developing Cell Recoding Molecules™, announced today that the results from a collaboration study with Prof. Alan E. Rowan (Radboud University, The Netherlands) were published in the current online edition of Nature Materials.

Read more »

Abcodia Announces Initial U.S. Availability of the ROCA® Test to Aid in the Early Detection of Ovarian Cancer

BOSTON, Mass. and CAMBRIDGE, England – Abcodia Ltd, a clinical stage company engaged in the commercial development of novel tests for the early detection of cancer, announced today the availability of the ROCA® Test for use by physicians in five U.S. states: Arizona, Illinois, Massachusetts, New Jersey and Texas. The test is already being used in the U.K. by private clinics and will become available in additional U.S. states throughout 2016.

Read more »

Premaitha establishes the first IONA® testing service in France at LaboSud

Manchester, UK and Montpellier, France  – Premaitha Health plc (AIM: NIPT, “Premaitha” or “the Company”) developer of the IONA® test, an advanced cell-free DNA prenatal screening test, has appointed Adgenix as its exclusive distributor in France. There are approximately 820,000 births per annum in France. Adgenix has already signed up its first laboratory customer for Premaitha in France, with a signed contract for a minimum of three years to supply LaboSud with the IONA® test.

Read more »

Innovations portfolio company Kesios Therapeutics raises £19 million in Series A funding round

London, UK - Imperial Innovations Group plc (AIM: IVO, ‘the Group’, ‘Innovations’) is pleased to announce that portfolio company Kesios Therapeutics (‘Kesios’ or ‘the Company’), which is developing novel therapeutics for the treatment of multiple myeloma and other cancers, has closed a £19.0 million Series A funding round from a syndicate of leading venture investors including Innovations, SV Life Sciences and Abingworth.

Read more »

Auspherix Appoints Dr. Neil Miller as Chief Scientific Officer

Stevenage, UK – Auspherix Limited (UK), an early stage anti-infectives company, has announced the appointment of Dr. Neil Miller as its Chief Scientific Officer, effective 1 December.

Read more »

GHO Capital acquires Quotient Clinical

London, UK – GHO Capital, the European specialist healthcare investor, today announces the acquisition of Quotient Clinical (Quotient or the Company), a provider of outsourced, early-stage drug development services to the pharmaceutical industry.

Read more »

Clinigen Group Initiates Managed Access Program for Ixazomib for Patients with Multiple Myeloma

London,UK - Clinigen Group plc’s (AIM: CLIN, ‘Clinigen’ or the ‘Group’) Managed Access division has initiated a Managed Access Program for ixazomib for patients with multiple myeloma. Ixazomib is developed and manufactured by Takeda Pharmaceutical Company Limited.

Read more »

ProAxsis presents new data to validate its ProteaseTag™ Active NE Immunoassay in chronic obstructive pulmonary disease patients

London, UK – NetScientific plc’s (“NetScientific” or the “Group”, AIM: NSCI) portfolio company, ProAxsis, a medical diagnostics spin-out from Queen’s University Belfast, will present new data that validates the use of its ProteaseTag™ Active Neutrophil Elastase (NE) Immunoassay in chronic obstructive pulmonary disease (COPD) patients for the first time.

Read more »

Ablynx appoints Robert K. Zeldin, MD, Chief Medical Officer

Ghent, Belgium - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced the appointment of Robert K. Zeldin, MD, as Chief Medical Officer (CMO). Effective from 1 December 2015, Dr Zeldin will lead the Company’s global clinical development, regulatory and medical affairs activities. Dr Zeldin brings significant industry experience to the Company, having held senior level clinical development positions at top tier pharmaceutical companies, including Merck & Co., Inc. and Novartis Pharmaceuticals Corp.

Read more »

Xellia Pharmaceuticals Expands US Production with Acquisition of Manufacturing Plant from Hikma Pharmaceuticals

Copenhagen, Denmark – Xellia Pharmaceuticals (‘Xellia’), a specialty pharmaceutical company focusing on providing important anti-infective treatments against serious and often life-threatening infections, has acquired manufacturing facilities in Bedford, Ohio from a wholly owned subsidiary of Hikma Pharmaceuticals PLC (‘Hikma’). Financial details are not disclosed.

Read more »

Ablynx Announces Nanobody Drug Discovery Collaboration with Novo Nordisk

Ghent, Belgium, - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced that it has entered into a global exclusive collaboration and licensing agreement with Novo Nordisk to discover and develop novel multi-specific Nanobody® drug candidates for use in an undisclosed disease area, with an option to expand the agreement to include a second Nanobody programme.

Read more »

Avita Medical Expands Commercial Reach for ReCell® in Wound Care Market with the Appointment of Distributors in France and the UK

Northridge, CA, USA and Cambridge, United Kingdom — Avita Medical Ltd. (ASX: AVH), (OTCQX: AVMXY), a regenerative medicine company specializing in the treatment of wounds and skin defects, today announced that it has entered into agreements with specialist wound-care distributors in France and the UK.

Read more »

Abcodia Appoints Richard A. Sandberg to its Board of Directors

Industry Veteran Brings Significant Diagnostics and Business Leadership Experience to Company to support US expansion

Read more »

Autifony Therapeutics initiates Phase I study of AUT00206, a novel treatment approach for schizophrenia

London, UK - Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for hearing loss and other serious brain disorders, today announced the start of Phase I clinical evaluation of its second Kv3 modulator, AUT00206. This is the first time that a Kv3 modulation mechanism has been applied to the treatment of schizophrenia. AUT00206 represents a novel class of Kv3 modulator which is being developed specifically for schizophrenia and related indications.

Read more »

Clinigen Group extends exclusive clinical trial distribution agreement with Accord Healthcare for another two years

Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or the ‘Group’) the global pharmaceutical and services company, announces that its global leading Clinical Trial Services business (Clinigen CTS) has renewed an exclusive European Union (EU) clinical trial distribution agreement with Accord Healthcare (‘Accord’), a wholly-owned marketing subsidiary of Intas Pharmaceuticals, for a further two years.

Read more »

Abzena plc: Half year results: Delivery, acquisition and growth

Cambridge, UK - Abzena plc (AIM:ABZA, ‘Abzena’ or the ‘Group’), a life sciences group providing services and technologies enabling the development and manufacture of biopharmaceutical products, publishes its half year results for the six months to 30 September 2015.

Read more »

Abzena plc: Placing to raise £20 million and acquisition

Cambridge, UK - Abzena plc (AIM:ABZA, ‘Abzena’ or the ‘Group’), a life sciences group providing services and technologies enabling the development and manufacture of biopharmaceutical products, has conditionally raised £20 million (net of expenses) by way of a placing of 35,004,972 new Ordinary Shares at 60 pence each with certain existing and new shareholders, and has agreed to acquire The Chemistry Research Solution LLC (“TCRS”), subject to certain closing conditions including completion of the placing. The Placing Price represents a 7.7 per cent discount to the closing mid-market price of an existing ordinary share on 23 November 2015, being the last business day prior to this announcement.

Read more »

AmpliPhi Signs Clinical Trial Agreement with University of Adelaide to Conduct a Phase I Trial of Bacteriophage Therapy for Treating Staphylococcus aureus Infections

San Diego and Richmond, Va., USA, Ljubljana, Slovenia, and Sydney, Australia - AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced that it has entered into a Clinical Trial Research Agreement with the University of Adelaide for the purpose of conducting a Phase I clinical study. The study is titled "A Phase I Investigator Initiated Study to Evaluate the Safety, Tolerability and Preliminary Effectiveness of AB-SA01 in Patients with Chronic Rhinosinusitis Associated with Staphylococcus aureus Infection".

Read more »

EP Vantage: PD-1/PD-L1 Combinations Drive the Development of New Immunotherapies

LONDON, BOSTON, TOKYO  – The immuno-oncology agents Keytruda and Opdivo have already transformed the cancer care landscape. Now specialists are pairing them with approved or experimental agents to improve on their already impressive efficacy, according to the “PD-1/PD-L1 Combination Therapies” report from EP Vantage, the editorial arm of market intelligence firm Evaluate Ltd. The EP Vantage analysis has identified over 150 PD-1/PD-L1 combinations currently in clinical development.

Read more »

Spiral laminar flow is the predominant flow pattern in 97% of volunteers in observational study

Dundee, UK – Vascular Flow Technologies (VFT), the medical device company using proprietary Spiral Laminar Flow™ (SLF™) technology to replicate natural blood flow for enhanced patient outcomes, has presented data showing that spiral laminar flow is the predominant flow pattern in arteries.

Read more »

Mucosis Presents Insights on Development of a Novel Needle-Free Vaccine for RSV Prevention at RSV Vaccines for World

Groningen, the Netherlands – Mucosis B.V., a clinical stage biotechnology company using a proprietary technology platform to develop next-generation needle-free human vaccines for infectious diseases, today presents key characteristics of its unique prefusion F antigen, the core technology behind its lead product, SynGEM®, an intranasally delivered, needle-free vaccine for the prevention of respiratory syncytial virus (RSV). Data were presented at the RSV Vaccines for World conference (RSVVW), taking place at the Salk Institute in La Jolla, California.

Read more »

Avita Medical Ltd. Receives Australian Patent

Patent protects Avita’s RESTM technology through 2033 and provides additional claim coverage

Read more »

Ablynx provides business update for the first nine months of 2015

GHENT, Belgium - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced its business update, summarising the non-audited financial position for the first nine months of 2015, material events since 30 September 2015 and the outlook for the next period.

Read more »

Crescendo Biologics Appoints Dr Kevin Johnson as Chairman

Cambridge, UK – Crescendo Biologics Limited (Crescendo), the drug discovery and developer of Humabody™ VH therapeutics, today announced the appointment of Dr. Kevin Johnson as non-executive Chairman of the Board of Directors. The appointment is effective immediately.

Read more »

GE Healthcare Life Sciences and Emerson team up to drive biopharma manufacturing efficiency

Chalfont St. Giles, UK and Austin, TX, USA – GE Healthcare’s Life Sciences business and Emerson Process Management, a global business of Emerson (NYSE: EMR), today announced a collaboration aimed at increasing productivity and improving efficiency in the production of biopharmaceuticals such as monoclonal antibodies and vaccines.

Read more »

ADC Therapeutics to Present Data on ADCT-301 and ADCT-402 at American Society of Hematology Annual Meeting

Lausanne, Switzerland, London, UK and Murray Hill, New Jersey, US – ADC Therapeutics (ADCT), the oncology drug development company today announced that it will be presenting at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place between 5-8 December in Orlando, Florida.

Read more »

Nanobiotix revenue for Q3 2015

Paris, France – NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announces its unaudited revenue for the third quarter of 2015.

Read more »

Nanobiotix’s Soft Tissue Sarcoma pivotal trial progressing well as planned: already 7 countries and 29 sites opened

Paris, France – NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces the dynamic expansion of its pivotal phase II/III trial for NBTXR3 in Soft Tissue Sarcoma (“act.in.sarc” study) in 29 sites in 7 countries. The patient recruitment rate is increasing in line with the Company’s expectations.

Read more »

Independent, multi-centre clinical study of the IONA® test in high risk pregnancies shows 100% detection of trisomies and 0% false positives

Manchester, UK – Premaitha Health PLC (AIM: NIPT, “Premaitha” or the “Company”), developer of the IONA® test, the first CE-marked non-invasive prenatal in vitro diagnostic kit (NIPT), announces the results of a study on first-trimester detection of trisomy 21, 18 and 13 in high risk pregnancies using the IONA® test1 which are published in the Journal of Ultrasound in Obstetrics and Gynecology.

Read more »

Abcam acquires AxioMx to access new growth opportunities and extend antibody leadership

• AxioMx provides a unique, cost-effective, and proprietary platform to produce recombinant monoclonal antibodies complementing Abcam's existing innovative production capabilities
• This in vitro technology will enable Abcam to offer new tools to existing and new customers working in technically challenging areas such as infectious disease, toxins, nucleotides, and membrane bound proteins
• AxioMx is already providing life science researchers, diagnostic companies, and drug discovery teams an efficient alternative to limitations they face with other systems

Read more »

AmpliPhi Announces Board Expansion with Appointment of Two Highly-Experienced Non-Executive Directors

San Diego and Richmond, VA, USA, Ljubljana, Slovenia, and Sydney, Australia -  AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced that Vijay B. Samant and Paul C. Grint, M.D. have been appointed to its Board of Directors as Non-Executive Directors.

Read more »

Abzena plc: Appointment of Campbell Bunce as Senior Vice President, Scientific Operations

Cambridge, UK – 10 November 2015 - Abzena plc (AIM:ABZA, ‘Abzena’), a life sciences group providing services and technologies that enable the development and manufacture of biopharmaceutical products, has appointed Dr Campbell Bunce to the new role of Senior Vice President, Scientific Operations.

Read more »

Avita Medical to Present at ARM’s 2015 EU Advanced Therapies Investor Day

Northridge, CA and Cambridge, United Kingdom — Avita Medical Ltd. (ASX: AVH), (OTCQX: AVMXY), a medical device company specializing in the treatment of wounds and skin defects, today announced that Chief Executive Officer Adam Kelliher will present and participate in a panel discussion at the Third Annual EU Advanced Therapies Investor Day being held Thursday, November 12, 2015 in London.

Read more »

NetScientific: Result of Placing and Further Allotment of New Shares Pursuant to Offer

London, UK - On 1 October 2015, the Group announced a conditional Placing to raise approximately £18.0m and an Additional Fundraising to raise up to approximately £2.0m, both before expenses.

Read more »

Ablynx’s partner Boehringer Ingelheim presented positive in vivo proof-of-mechanism data with bi-specific nanobody at Euro Global Summit on Cancer Therapy

Ghent, Belgium - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced that its partner Boehringer Ingelheim presented positive in vivo proof-of-mechanism data from the half-life extended bi-specific anti-VEGF/Ang2 Nanobody, at the 8th Euro Global Summit on Cancer Therapy, taking place 3-5 November 2015 in Valencia, Spain.

Read more »

Clinigen Group and United Therapeutics Initiate Managed Access Program for UNITUXIN™ (Dinutuximab) Injection for High Risk Neuroblastoma

Clinigen Group plc’s (AIM: CLIN, ‘Clinigen’ or the ‘Group’) Idis Managed Access (MA) division and United Therapeutics Corporation (‘United Therapeutics’), a biotechnology company focused on the development and commercialization of products for chronic and life-threatening conditions, have initiated a Managed Access program for UNITUXIN™ (dinutuximab) injection.

Read more »

Review of haemodynamics in stent development shows spiral flow may be key to improving peripheral arterial stent performance

Review in Annals of Biomedical Engineering suggests re-introduction of spiral flow after endovascular treatment for PAD may support endothelial function and increase patency rates

Read more »

DNAe Secures £25 million ($38 million) Bank Facility to Fund Development of Pioneering Point-of-Need IVD for Serious Blood Infections

Bank facility will enable development of Genalysis® platform and bloodstream infection assays through to launch

Read more »

Clinigen Group plc: Completion of Acquisition of Link

Clinigen Group plc (AIM: CLIN, "Clinigen" or the "Group"), the global specialty pharmaceuticals business, has today completed the acquisition of Link Healthcare Private Limited ("Link") which was announced on 22 September 2015 (the "Acquisition").

Read more »

Clinigen Group plc: Board appointment

Clinigen Group plc (AIM: CLIN, "Clinigen" or the "Group"), the global specialty pharmaceuticals business, announces that upon completion earlier today of the acquisition of Link Healthcare Private Limited ("Link") (the "Acquisition") (see separate announcement), John Bacon joined the Group as a Non-Executive Director. Johannes Willemse will act as John Bacon’s alternate on the Clinigen board (the “Board”).

Read more »

Sun Biomedical’s Technology Recognised in Leading Peer Review Publication

Melbourne and Perth, Australia - Sun Biomedical Limited (ASX: SBN) today announced the publication of a peer review article highlighting the broad commercial applicability of the company’s patented assay technology. The article is co-authored by Chief Scientific Advisor, Associate Professor Kevin Pfleger and refers to Dimerix (Sun Biomedical).

Read more »

e-Therapeutics: Appointment of Non-Executive Director

Oxford and Newcastle - e-Therapeutics plc (AIM: ETX), the drug discovery and development company, announces the appointment of Professor Trevor Mervyn Jones CBE, aged 73, to the Board of Directors as a Non-Executive Director.

Read more »

Premaitha Health Plc Appointment to the Board

Manchester, UK – Premaitha Health PLC (AIM: NIPT, “Premaitha” or the “Company”), developer of the IONA® test, the first CE-marked non-invasive prenatal screening test (NIPT) confirms that Chief Medical Officer, Dr William Denman, will join the Board of Premaitha as an Executive Director on 1 November 2015.

Read more »

Avita Medical Presents Research Demonstrating Treatment Power of ReCell® in Burns

Academic Papers Presented at 16th European Burns Association Congress

Read more »

AGM Statement

Clinigen Group plc (AIM: CLIN, "Clinigen" or the "Group"), the global specialty pharmaceuticals business, is holding its Annual General Meeting (“AGM”) at 10.00am today at Instinctif Partners’ offices, 65 Gresham Street, London EC2 7NQ.

Read more »

Sun Biomedical Limited Expands Kidney Disease Study Sites

Melbourne and Perth, Australia - Sun Biomedical Limited (ASX: SBN) is pleased to announce the addition of a fourth site to its Phase II clinical study into the safety and efficacy of a new treatment for kidney disease.

Read more »

Vascular Flow Technologies launches Spiral Flow™ PV Bypass Graft registry in Germany

Dundee, UK – Vascular Flow Technologies, the medical device company using proprietary Spiral Laminar Flow™ (SLF™) technology to replicate natural blood flow for enhanced patient outcomes, today announces the launch of its Spiral Flow™ PV Bypass Graft registry at the 31st annual Deutschen Gesellschaft für Gefäßmedezin (DGG) in Münster.

Read more »

Avita Medical Announces First Patient Treated in US Military Wound Trial

Northridge CA and Cambridge, UK — Avita Medical Ltd. (ASX: AVH), (OTCQX: AVMXY), a regenerative medicine company specializing in the treatment of wounds and skin defects, today announced that doctors at a leading US military hospital have started a trial to investigate how the Company’s ReCell® device can be used to treat traumatic wounds suffered by civilians and wounded military personnel.

Read more »

Instinctif Partners hosts first ‘Media Question Time’ BioWednesday with One Nucleus

London: Instinctif Partners, the business communications consultancy, sponsored and hosted its first BioWednesday event - ‘Media Question Time’ - with One Nucleus, the international membership organisation for life science and healthcare companies, on Wednesday, 7th October 2015.

Read more »

Puridify completes Series A funding for commercialisation of single-use nanofibre-based purification technology

London, UK – Puridify Limited (“Puridify”), developers of novel bioprocessing purification technologies for industrial biomolecule manufacture, today announced the closing of a £2.2 million Series A funding round. This follow-on investment by existing investors Imperial Innovations, SR One and UCL Business, brings the total raised including grant funding to £8 million, and is a strong expression of confidence in the company and the progress of its proprietary nanofibre purification platform, FibroSelect.

Read more »

Ablynx Achieves First Milestone In Immuno-Oncology Collaboration With Merck & Co., Inc.

GHENT, Belgium - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced that it has achieved pre-clinical proof-of-concept with a Nanobody construct  as part of its immuno-oncology collaboration with Merck & Co., Inc. (“Merck”) [known as MSD outside the United States and Canada], triggering a €3.5 million milestone payment to Ablynx. This collaboration with Merck includes the discovery and development of up to 17 Nanobody programmes against individual protein targets and target combinations (mono-specific and multi-specific Nanobodies) for application in immuno-oncology indications.

Read more »

Near doubling of investment rate and gains in unquoted portfolio drive net portfolio value up by £75.2 million to £327.2 million

Imperial Innovations Group plc (AIM: IVO, "Innovations" or "the Group"), a leading technology commercialisation and investment group, has published its results for the year ended 31 July 2015.

Read more »

Crescendo Biologics Launches New Strategy in Oncology Drug Discovery & Development

Cambridge, UK – Crescendo Biologics Limited (Crescendo), the drug discovery and developer of Humabody™ VH therapeutics, today announced the launch of the Company’s new drug development strategy.

Read more »

Premaitha opens dedicated clinical laboratory with expanded capacity to meet demand for IONA® test service

Manchester, UK – Premaitha Health plc (AIM: NIPT, “Premaitha” or “the Company”), developer of the IONA® test, the first CE-marked non-invasive prenatal screening test (NIPT) has expanded its in-house NIPT screening service by opening a dedicated laboratory which triples clinical capacity in response to demand for the IONA® test from clinicians.

Read more »

GHO Capital announces acquisition of DNA Diagnostics Center

London, UK – 13 October 2015 – GHO Capital, the European specialist healthcare investor, today announces the acquisition of DNA Diagnostics Center (DDC or the Company), a world leader in the provision of specialist DNA-based diagnostic services, for a total transaction value of €104 million. Further details of the transaction were not disclosed.

Read more »

Premaitha Health PLC AGM Statement

Manchester, UK – Premaitha Health PLC (AIM: NIPT, “Premaitha” or the “Company”) will hold its AGM today at 3pm at the Dalton Room, The Innovation Centre, University of Manchester, 46-48 Grafton Street, Manchester, M13 9XX.

Read more »

In-house Antenatal reflex DNA screening for Down’s syndrome, trisomy 18 and trisomy 13: a world first

The Wolfson Institute of Preventive Medicine with the assistance of Premaitha Health plc (AIM: NIPT), is launching an in-house antenatal reflex DNA screening service on 19 October 2015. The DNA screening test estimates the risk of having a pregnancy with Down’s syndrome, trisomy 18 (Edwards syndrome) or trisomy 13 (Patau syndrome) by analysing cell free DNA from a sample of maternal blood.

Read more »

Premaitha: Independent performance study of the IONA® test published

Manchester, UK – Premaitha Health plc (“Premaitha” or “the Company”, AIM: NIPT), developer of the IONA® test, the first CE-marked non-invasive prenatal screening test (NIPT), announces the results of a study on the first-trimester detection of trisomy 21, 18 and 13 using the IONA® test1. The study was undertaken by a team led by Professor Kypros Nicolaides with Dr Liona Poon as the lead author at the Harris Birthright Research Centre for Fetal Medicine, King’s College Hospital, London, and was published in the Journal of Ultrasound in Obstetrics and Gynaecology.

Read more »

Adheron Therapeutics is acquired by Roche for its therapeutic antibody

Cambridge, UK - Abzena plc (AIM:ABZA), a life sciences Group providing services and technologies that enable the development and manufacture of biopharmaceutical products, notes the announcement today of the acquisition by Roche (SIX: RO, ROG; OTCQX: RHHBY) of Adheron Therapeutics ("Adheron").

Read more »

TranScrip strengthens its Board

Reading, UK – TranScrip is delighted to announce that it has made two recent additions to its Board, Dr Frank Armstrong and Dr Linda Summerton.

Read more »

National Institute of Health Research Clinical Research Network Adopts Spiral Flow™ AV Graft Randomised Controlled Trial

Dundee, UK – Vascular Flow Technologies, the medical device company using proprietary Spiral Laminar Flow™ (SLF™) technology to replicate natural blood flow for enhanced patient outcomes, today announces the adoption of its randomised controlled trial (RCT) of the Spiral Flow™ AV graft for use in arteriovenous haemodialysis access in end-stage renal disease (ERSD) by the National Institute of Health Research Clinical Research Network (NIHR CRN).

Read more »

Premaitha appoints Antisel SA to distribute the IONA® test in Greece

Manchester, UK and Athens, Greece – Premaitha Health plc (“Premaitha” or “the Company”, AIM: NIPT), developer of the IONA® test, the first CE-marked test for non-invasive prenatal screening (NIPT), has signed a distribution agreement with Antisel SA (“Antisel”), the leading distributor of scientific products in Greece, to provide the IONA® test to clinical laboratories in the region.

Read more »

Premaitha Health: Illumina Patent Infringement Proceedings Update

Manchester, UK – Premaitha Health plc ("Premaitha" AIM: NIPT) an innovative molecular diagnostics company employing the latest advances in DNA analysis technology to develop tests for non-invasive prenatal testing (NIPT) has been informed that Illumina, Inc. has today added a third patent to the two previously asserted in a UK patent suit against Premaitha in the High Court of Justice, Chancery Division, Patents Court in the UK.

Read more »

Australian Biopharmaceutical Company, Paranta Biosciences, Raises AUD$7 million and Starts First Human Clinical Trial of Promising New Therapeutic for Cystic Fibrosis

Melbourne, Australia - Private Australian biopharmaceutical company Paranta Biosciences Limited has successfully closed an AUD$7 million financing round. Since commencing operations in 2011, the Company has raised AUD$16 million.

Read more »

NetScientific: Proposed Placing to raise approximately £18.0 million

London, UK - NetScientific plc (AIM:NSCI), a transatlantic biomedical healthcare group with a differentiated investment strategy focused solely on digital health, diagnostics and therapeutics, announces a conditional Placing to raise approximately £18.0 million before expenses and an Additional Fundraising to raise up to approximately £2.0 million, primarily to accelerate the development of its two lead portfolio companies, Vortex Biosciences and Wanda, towards significant value inflection milestones and exits. Neither the Placing nor the Additional Fundraising are underwritten.
 

Read more »

NetScientific: Half Year Results for the six months ended 30 June 2015

London, UK - NetScientific (AIM: NSCI), the transatlantic biomedical and healthcare technology group today announced its half year results for the six months ended 30 June 2015.

Read more »

New Independent Data on Adherium Smartinhaler™ Clinical Outcomes Shows Increased Adherence and Reduction in Severe Attacks

Melbourne, Australia - Adherium Limited (ASX: ADR), a global leader in digital health technologies which address sub-optimal medication use in chronic disease; today announced that data from three independent studies demonstrating the efficacy of the Company’s Smartinhaler™ platform in paediatric asthma management will be presented at the European Respiratory Society International Congress, taking place 26-30 September in Amsterdam, The Netherlands.

Read more »

Instinctif Partners Life Sciences’ Clients Shortlisted for OBN and Scrip 2015 Industry Awards

London, Manchester: Instinctif Partners Life Science supports its clients with entries to awards and is delighted that this month its clients have been shortlisted for a number of Awards including the OBN 2015 Awards and the 2015 Scrip Awards.

Read more »

Media Question Time

One Nucleus BioWednesday event sponsored and hosted by Instinctif Partners, co-sponsored by Coulter Partners

Wednesday 7 October 2015
65 Gresham Street, EC2V 7NQ (near St Paul’s)
5pm (registration) – 9pm (close)

For a chance to put key life science media on the spot join us for a 60-minute Q&A session, which will bring a great opportunity for those who engage with the media (CEOs, CFOs etc) to quiz leading journalists on new trends and best practice, and for media experts to discuss how best to work with them.

Read more

Read more »

Discovery Platform Exceeding Expectations; Company Focus Now on Commercialisation

 Oxford and Newcastle - e-Therapeutics plc (AIM: ETX), the drug discovery and development company, today announces its half year results for the six months ended 31 July 2015.

Read more »

Ablynx Initiates a Multinational Phase III Study with Caplacizumab in Patients with Acquired TTP, a Rare Blood Clotting Disorder

GHENT, Belgium - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced the initiation of a multinational, double-blind placebo-controlled Phase III “HERCULES” study evaluating efficacy and safety of caplacizumab, its wholly-owned anti-vWF Nanobody, in acquired TTP.  The study is expected to enrol 92 patients at clinical sites across 17 countries.

Read more »

New Independent Data on Adherium Smartinhaler Clinical Outcomes in Paediatric Asthma to be Presented at European Respiratory Congress

Melbourne, Australia - Adherium Limited (ASX: ADR), a global leader in digital health technologies which address sub-optimal medication use in chronic disease; today announced that data from three independent studies demonstrating the efficacy of the Company’s Smartinhaler™ platform in paediatric asthma management will be presented at the European Respiratory Congress, taking place between 26-30 September in Amsterdam, The Netherlands.

Read more »

Clinigen to acquire Link Healthcare to strengthen position across Asia, Africa and Australasia

Burton-on-Trent, UK - Clinigen Group plc (‘Clinigen’  or the ‘Group’, AIM: CLIN), the specialty global pharmaceutical company, has agreed to acquire Link Healthcare (‘Link’), a specialist pharmaceutical and medical technology business focussed on the Asia, Africa and Australasia (‘AAA’) region, for an initial consideration of £44.5 million and a maximum of approximately £100 million based on achievement of milestones (the ‘Acquisition’).

Read more »

Premaitha signs first non-European partnership with Servicios Genéticos OriGen to provide the IONA® test for pregnant women in Chile

Manchester, UK and Santiago, Chile – Premaitha Health plc (“Premaitha” or “the Company”, AIM: NIPT), developer of the IONA® test, the first CE-marked non-invasive prenatal screening test (NIPT) has signed an agreement with Servicios Genéticos OriGen (“OriGen”), a private laboratory group in Santiago, Chile. This is Premaitha’s first partnership outside of Europe and helps expand the IONA® test’s reach to meet the growing global demand for NIPT.

Read more »

Results for the financial year ended 31 March 2015

Manchester, UK – Premaitha Health PLC (AIM: NIPT, “Premaitha” or the “Company”) announces its results for the financial year ended 31 March 2015, and provides notice of its Annual General Meeting.

Read more »

Clinigen Group: Great Strides Made in Strategic Priorities, with Underlying EBITDA up 20%

Clinigen Group plc (AIM: CLIN, ‘Clinigen’, or the ‘Group’), the global specialty pharmaceuticals business, has today published its full year results for the 12 months ended 30 June 2015.

Read more »

Clinigen Group and Neuraltus Pharmaceuticals Announce Partnership to Initiate a Managed Access Program for Investigational ALS Therapy in Europe

Clinigen Group plc’s (‘Clinigen’ or the ‘Group’, AIM: CLIN) Idis Managed Access (MA) division and Neuraltus Pharmaceuticals, Inc., a privately-held biopharmaceutical company focused on the development of drugs to treat neurodegenerative diseases, announced today that the companies are partnering to initiate a Managed Access program for NP001, Neuraltus’ investigational therapy for amyotrophic lateral sclerosis (ALS). The partnership makes the Managed Access program immediately available in selected European countries and is expected to gradually expand over the next year.

Read more »

AmpliPhi Announces Data Demonstrating Efficacy of a Novel Bacteriophage Cocktail is Comparable to Vancomycin in S. aureus Lung Infection Model

San Diego and Richmond, VA, USA, Ljubljana, Slovenia, and Sydney, Australia – AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced experimental results highlighting that its prototype bacteriophage cocktail demonstrated comparable efficacy to vancomycin in reduction of Staphylococcus aureus (S. aureus) in a murine lung infection model. Data from this study, performed in collaboration with the Hearts Consulting Group and the University of North Texas (UNT) Health Science Center, were presented at the joint Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC) and International Congress of Chemotherapy and Infection (ICC) 2015 meeting, taking place in San Diego from September 17-21.

Read more »

Abcam appoints Mara Aspinall as Non-Executive Director

Cambridge UK: Abcam plc, a global leader in the supply of life science research tools, is pleased to announce that Mara Glickman Aspinall will join the Board of Abcam as a non-executive director, with immediate effect.

Read more »

Clinigen Group signs strategic alliance with Cumberland Pharmaceuticals

Clinigen Group plc (‘Clinigen’ or the ‘Group’, AIM: CLIN), the global pharmaceutical and services company, has agreed to a strategic alliance with Cumberland Pharmaceuticals Inc. (‘Cumberland’, NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care. The alliance will combine Clinigen’s and Cumberland’s respective strengths, expertise and geographical footprints to maximize the commercial potential of future products.

Read more »

Amgen acquires Forbion portfolio company Dezima Pharma

Naarden, The Netherlands – Forbion Capital Partners (“Forbion”), one of the leading Dutch venture capital firms investing in world-class healthcare technologies, announces that its portfolio company, Dezima Pharma (‘Dezima’), the biotechnology company developing innovative drugs to treat dyslipidemic patients suffering from cardiovascular disease (CVD), will be acquired by Amgen, Inc. (NASDAQ: AMGN).

Read more »

Auspherix and Domainex Expand Collaboration to Develop New Drugs that Tackle Antibiotic-Resistant Bacterial Infections

Cambridge, UK and Stevenage, UK  - Domainex and Auspherix today announce an expansion of their collaboration to develop new drugs to tackle the growing threat of resistance to antibiotics. The programme has been extended through to 2017.

Read more »

Sun Biomedical (ASX: SBN) Initiates Phase II Clinical Trial of Promising Combination Therapy for Chronic Kidney Disease

Melbourne Australia - Sun Biomedical Limited (ASX: SBN) today announced the first patient had been enrolled in a Phase II study of DMX-200, an innovative new treatment that combines two different drugs to treat chronic kidney disease.

Read more »

Forbion announces the closing of FCF II Co-invest Fund I at EUR 75M

Naarden, The Netherlands - Expanding on its successful co-investment program, Forbion is pleased to announce the closing of its Forbion Capital Fund II Co-invest Fund I (FCF II Co-Invest) at EUR 75M. This new fund vehicle has been set up to allow Forbion’s existing LPs to back later-stage, de-risked companies within the existing FCF II portfolio with additional (growth) capital.

Read more »

Abcam raises antibody validation standards to improve quality for life science researchers

Cambridge UK – Abcam plc, a global leader in the supply of life science research tools, today announced an industry-changing antibody validation initiative to address the critical need for antibodies with a higher target specificity.

Read more »

AmpliPhi Biosciences to Present at Rodman & Renshaw 17th Annual Global Investment Conference

San Diego and Richmond, VA, USA, Ljubljana, Slovenia, and Sydney, Australia – AmpliPhi Biosciences Corporation (NYSE: APHB), a global leader in developing bacteriophage-based antibacterial therapies to treat drug resistant infections, today announced that M. Scott Salka, CEO, will present a corporate overview on Thursday, September 10 at the Rodman & Renshaw 17th Annual Global Investment Conference taking place at the St. Regis Hotel in New York.

Read more »

Forbion invests in Sanifit’s €36.6M ($41M) Series C financing round

Naarden, The Netherlands – Forbion Capital Partners (“Forbion”), one of the leading Dutch Venture Capital firms investing in world-class healthcare technologies, announces its investment in Laboratoris Sanifit S.L. (“Sanifit”), a Spanish clinical-stage biopharmaceutical company, as part of Sanifit’s €36.6M ($41M) Series C financing round.

Read more »

Oxford Gene Technology focuses on high growth genomics products Cytocell®, CytoSure™, and SureSeq™

Oxford and Cambridge, UK – Oxford Gene Technology (OGT), the molecular genetics company, today announces a strategic realignment of its commercial operations to fuel further growth in its high value genomics products portfolio. As part of this realignment, OGT will transfer its next generation sequencing services business to Source BioScience (LSE: SBS). Financial details were not disclosed.

Read more »

Dr John Hutchison joins Autifony Therapeutics as Chief Medical Officer

London, UK - Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for hearing disorders, today announced that Dr John Hutchison has joined the company as Chief Medical Officer, ahead of the planned retirement of Dr Peter Harris at the end of September.

Read more »

AmpliPhi Biosciences Announces Appointment of Alexander Gaidamaka as Vice President of Chemistry, Manufacturing and Control

San Diego and Richmond, VA, USA, Ljubljana, Slovenia, and Sydney, Australia – AmpliPhi Biosciences Corporation (NYSE: APHB), a global leader in developing bacteriophage-based antibacterial therapies to treat drug resistant infections, today announced that Alexander Gaidamaka, Ph.D., D.V.M, has been appointed as the new Vice President of Chemistry, Manufacturing and Control.

Read more »

ADC Therapeutics Secures $80m Financing to Progress its Pipeline of Antibody Drug Conjugate Therapeutics in Oncology

Lausanne, Switzerland and London, UK and Murray Hill, New Jersey, US – ADC Therapeutics (ADCT), an oncology drug discovery and development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major cancers, today announced that it has raised $80 million through a private placement of equity. New investors include leading European and US-based investors alongside founding investor Auven Therapeutics and participation from AstraZeneca.

Read more »

Sartorius Stedim Biotech and GE Healthcare sign worldwide OEM supply agreement

Aubagne, France; Goettingen, Germany and Chalfont St. Giles, UK – Sartorius Stedim Biotech, a leading international supplier for the biopharmaceutical industries and GE Healthcare’s Life Sciences business, a provider of start-to-finish enterprise solutions, technologies and services for biopharmaceutical manufacturing, today announced they have entered into a worldwide OEM supply agreement for Sartorius Stedim Biotech’s innovative membrane adsorber purification technology, Sartobind™. Under the terms of the agreement, SSB will manufacture membrane adsorber technologies for GE which will be marketed as part of GE’s ReadyToProcess™ product offerings. Membrane adsorber ion-exchange technology is widely used in the industry for the removal of contaminants such as endotoxins and viruses during the production of protein-based drugs, and can offer manufacturers advantages compared to other techniques. Financial terms were not disclosed.

Read more »

coramaze technologies raises EUR 4.5 million to advance novel transfemoral mitral valve repair system into the clinic

Munich, Germany – coramaze technologies GmbH, a German medical device company, is developing the mitramaze® valve repair system – a novel concept for transcatheter mitral valve repair (TMVRep) intended for treatment of inoperable patients suffering from severe functional mitral regurgitation (fMR). coramaze announced today the closing of a EUR 4.5 million (US$ 5.15 million)  series A financing round led by Elron Electronic Industries Ltd, a leading Israeli holding company dedicated to building technology companies, primarily in the field of medical devices. Current investors High-Tech Gründerfonds and SeedCapital Dortmund joined this funding round alongside a pool of private investors.

Read more »

Forbion Announces - Bristol-Myers Squibb Enters Agreement Providing Exclusive Right to Acquire Promedior, Inc. and its Novel PRM-151 in Development for Fibrotic Diseases

Naarden, The Netherlands - Forbion Capital Partners, a leading Dutch Venture Capital firm investing in world-class healthcare technologies, is proud to announce that Bristol-Myers Squibb Company (NYSE: BMY) and Promedior, Inc. announced the companies have entered into an agreement that grants Bristol-Myers Squibb an exclusive right to acquire Promedior and gain worldwide rights to its lead asset PRM-151, a recombinant form of human pentraxin-2 protein in Phase 2 development for the treatment of idiopathic pulmonary fibrosis (IPF) and myelofibrosis (MF). PRM-151 has been granted Fast Track designation in the U.S. and Orphan designation in the U.S. and Europe for the treatment of MF and Orphan Designation in the U.S. and Europe for the treatment of IPF. Promedior is a clinical stage immunotherapy company pioneering the development of targeted therapeutics to treat fibrotic diseases.  Total aggregate payments to Promedior under the agreement have the potential to reach $1.25 billion, which includes an upfront cash payment for the right to acquire Promedior, an exercise fee payable if Bristol-Myers Squibb elects to exercise its right to acquire the company, and subsequent clinical and regulatory milestone payments.

Read more »

Nanobiotix Half Year Results For The SIX Months Ended 30 June 2015, In Line With Expectations

Paris, France – NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces its half year results for the six months ended 30 June 2015.

Read more »

Instinctif Partners congratulates its clients and all shortlisted nominees for the AIM Awards 2015

London, UK: Instinctif Partners, the business communications consultancy, congratulates all the nominees shortlisted for the AIM Awards 2015.

Read more »

Ablynx Announces Half-Year Results for 2015

Ghent, Belgium - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced its business update and results for the six-month period ending 30 June 2015, which have been prepared in accordance with the IAS 34 “Interim Financial Reporting” as adopted by the European Union.

Read more »

Big Changes for Medtech in First Half of 2015 While Pharma Set To Break Records

London, Boston, Tokyo - The first half of 2015 has continued to confound the naysayers of the pharma industry, with deal making, venture funding and share price indices all going strong. Meanwhile, the medtech sector is much changed from a year or even six months ago, with some of the biggest names shifting to take a larger share of the market and others moving out of it altogether.

Read more »

AmpliPhi Biosciences Announces Approval of Common Stock Listing on NYSE MKT

San Diego and Richmond, VA, USA, Ljubljana, Slovenia, and Sydney, Australia – AmpliPhi Biosciences Corporation (OTCQB: APHBD), a global leader in developing bacteriophage-based antibacterial therapies to treat drug resistant infections, today announced that its shares of common stock have been approved for listing on the NYSE MKT, subject to continued satisfaction of listing requirements. The company anticipates its common stock will begin trading on the NYSE MKT under the ticker APHB on August 21, 2015.

Read more »

Half year trading and commercial strategy update

Oxford and Newcastle, UK - e-Therapeutics plc (AIM: ETX), the drug discovery and development company today provides a trading update for the six month period to 31 July 2015 and further information on its commercial strategy.

 

 

Read more »

AmpliPhi Reports Second Quarter 2015 Financial Results and Provides Corporate Update

San Diego, CA and Richmond, VA, USA, Ljubljana, Slovenia, and Sydney, Australia – AmpliPhi Biosciences Corporation (OTCQB: APHBD), a global leader in the development of bacteriophage-based antibacterial therapies to treat antibiotic-resistant infections, today reported financial results for the second quarter ended June 30, 2015 and highlighted operational achievements.

Read more »

Xellia Pharmaceuticals Expands Raleigh, NC Site to Become New North American Headquarters

Copenhagen, Denmark and Raleigh, North Carolina – Xellia Pharmaceuticals (‘Xellia’), a specialty pharmaceutical company focusing on providing important anti-infective treatments, announces the expansion of its Raleigh, NC site to enable the relocation of its North American headquarters from Grayslake, Illinois.

Read more »

NetScientific divests non-core assets to align its healthcare portfolio

London, UK - NetScientific plc ("NetScientific" or the "Group", AIM: NSCI), the transatlantic biomedical and healthcare technology group, announces that as part of an ongoing review of its portfolio, it has started to divest certain projects that fall outside of its core areas of focus.

Read more »

AmpliPhi to Present at the 21st Biennial Evergreen International Phage Meeting

San Diego and Richmond, VA, USA, Ljubljana, Slovenia, and Sydney, Australia – AmpliPhi BioSciences Corporation (OTCQB: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, announced that the Company will give a presentation today at the 21st Biennial Evergreen International Phage Meeting, taking place August 2-7 in Olympia, Wash.

Read more »

AmpliPhi BioSciences Cleared to Submit Listing Application to NYSE MKT

San Diego and Richmond, VA, USA, Ljubljana, Slovenia, and Sydney, Australia – AmpliPhi BioSciences Corporation (OTCQB: APHB), a global leader in developing bacteriophage-based antibacterial therapies to treat drug resistant infections, today announced that its board of directors has approved a one-for-fifty reverse split of the company’s common stock to become effective at market open on August 07, 2015. The company has also been cleared to submit an application to the NYSE MKT for a planned uplisting. AmpliPhi’s eligibility is subject to NYSE MKT rules and regulations and maintaining a minimum market price per share for a specified time period as determined by the NYSE.

Read more »

Innovations leads £2.5m funding round in Oxford Biotrans

London, UK - Imperial Innovations Group plc (AIM: IVO, ‘the Group’, ‘Innovations’) has completed a £2.5m Series A funding round in Oxford Biotrans, a University of Oxford spin-out company, which is pioneering the commercialisation of biocatalytic processes for the production of high value specialty chemicals, based on its patented enzyme technology.

Read more »

ProAxsis launches first-in-class ProteaseTag test for Cystic Fibrosis and Chronic Obstructive Pulmonary Disease

London, UK – NetScientific portfolio company, ProAxsis, a medical diagnostics spin-out from Queen’s University Belfast, has officially launched its proprietary first-in-class ProteaseTag™ immunoassay kits to research labs and announces its first two customer orders, including a major pharma company.

Read more »

OGT expands Next Generation Sequencing portfolio

Oxford and Cambridge, UK – Oxford Gene Technology (OGT), the molecular genetics company, today announces the expansion of its portfolio of high-quality products for Next Generation Sequencing (NGS) with the addition of the SureSeq™ Ovarian Cancer Panel & SureSeq NGS Library Preparation Kit.

Read more »

Ablynx initiates Phase II SLE study with its Anti-IL-6R nanobody, partnered with Abbvie

Ghent, Belgium - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced that it has administered the first dose in the Phase II STEADY study to evaluate the efficacy and safety of its anti-IL-6R Nanobody®, ALX-0061, administered subcutaneously in adult patients with moderate to severe, active seropositive SLE, despite receiving the standard-of-care. The study also aims to identify the optimum dose and frequency of administration of ALX-0061 for the next phases of development.

Read more »

AmpliPhi to Present Research on Efficacy of a Novel Bacteriophage Cocktail in S. aureus Lung Infection Model at ICAAC/ICC 2015

San Diego and Richmond, VA, USA, Ljubljana, Slovenia, and Sydney, Australia – AmpliPhi BioSciences Corporation (OTCQB: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, today announced that data comparing the efficacy of its bacteriophage cocktail to vancomycin in a Staphylococcus aureus lung infection mouse model will be presented at the joint Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC) and International Congress of Chemotherapy and Infection (ICC) 2015 meeting, September 17-21 in San Diego.

Read more »

European Technology Platform for Nanomedicine and ENATRANS European Consortium Launch the 2nd edition of the Nanomedicine Award

Berlin – The European Technology Platform for Nanomedicine (ETPN) and the EU-funded consortium, ENATRANS, have launched the second edition of the Nanomedicine Award to honor the best international nanomedicine innovations for 2015.

Read more »

Adherium & AstraZeneca Partner to Improve the Lives of Individuals with Respiratory Disease

Auckland, New Zealand - New Zealand-based Adherium (NZ) Limited has entered a long term partnership with international pharmaceutical leader AstraZeneca in what the company believes is a world-first commercial arrangement combining digital health technology with blockbuster inhaler medications to improve health outcomes for patients with respiratory conditions.

Read more »

Auspherix Expands Board of Directors and Scientific Advisory Board

Stevenage, UK – Auspherix Limited (UK), an early stage anti-infectives company, has announced that it has expanded and strengthened its Board and Scientific Advisory Board with the appointments of Dr Jared Silverman as Non-Executive Director and Scientific Advisor, and Professor David Livermore as a Scientific Advisor.

Read more »

LEUKOCARE receives growth capital funding by LifeCare Partners and strengthens its board with industry experts

Munich, Germany - LEUKOCARE, a leading provider of stabilizing and protecting formulation technologies for proteins and other biologics, today announced the closing of its latest financing round providing growth capital to the company. The round was led by LifeCare Partners, a dedicated venture capital and private equity firm in the European healthcare sector, with participation from a group of new investors and current shareholders.

Read more »

Clinigen Group plc: Year end trading update

Clinigen Group plc (‘Clinigen’ or the ‘Group’, AIM: CLIN), the global pharmaceutical and services company, today provides a trading update for the year ended 30 June 2015.

Read more »

Ablynx significantly expands its immuno-oncology collaboration with Merck & Co., inc.

GHENT, Belgium - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced an expansion of its immuno-oncology collaboration with a subsidiary of Merck & Co., Inc. (“Merck”) [known as MSD outside the United States and Canada], to address an increased number of immune checkpoint modulator targets.

Read more »

Nanobiotix revenue for Q2 2015

Paris, France – NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announces its revenue for the second quarter of 2015.

Read more »

NOXXON appoints Aram Mangasarian as CEO

Berlin, Germany and Boston, USA – NOXXON Pharma has appointed Dr. Aram Mangasarian as the new CEO. He is taking over from Iain Buchanan, who will be nominated to join the Supervisory Board as a non-executive director.

Read more »

Autifony Therapeutics extends Series A with £8 million for hearing disorders and schizophrenia clinical trials

London, UK - Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for hearing disorders, today announced the closing of an £8 million extension to its Series A funding round.

Read more »

Seventure Partners invests EUR 2 Million Series A in CRISPR-based, microbiome company, Eligo Bioscience

Paris, France – Seventure, one of Europe’s leaders in financing innovation and visionary investor in the microbiome field since 2008, today announced the investment of €2m in a Series A financing for Eligo Bioscience. Seventure has led this round.

Read more »

Clinigen Group Awarded ServiceMark for Consistent World-Class Customer Service

Clinigen Group plc (‘Clinigen’ or the ‘Group’, AIM: CLIN) the specialty global pharmaceutical company, has been awarded the ServiceMark accreditation by The Institute of Customer Service (‘The Institute’) in recognition of the Group’s commitment to, and achievement in customer services.

Read more »

Vascular Flow Technologies expands global patent landscape with three new patents in Japan, China and Europe

Dundee, UK – Vascular Flow Technologies, the medical device company using proprietary Spiral Laminar Flow (SLF™) technology to replicate natural blood flow for enhanced patient outcomes, today announces the issue of three new patents, expected to strengthen the Company’s offering in both Asian and global markets.

Read more »

Premaitha Health receives CQC accreditation for new NIPT clinical service laboratory to support IONA® test customers

Manchester, UK – Premaitha Health plc (“Premaitha” or “the Company”, AIM: NIPT), developer of the IONA® test, the first CE-marked non-invasive prenatal screening test (NIPT), has received Care Quality Commission (CQC) accreditation for its new NIPT service laboratory.

Read more »

Premaitha Health: Completion of placing to raise £8 million

Manchester, UK – Premaitha (AIM: NIPT) has successfully completed the placing announced earlier today (the “Placing”).

Read more »

Imperial Innovations: Innovations leads £4.0m funding round in Impression Technologies

Imperial Innovations Group plc (AIM: IVO, "Innovations", “the Group”) has led a £4.0 million funding round in Impression Technologies Ltd. (“Impression Technologies” or the “Company”), an aluminium forming technology business based on intellectual property developed at Imperial College London.

Read more »

Premaitha Health: Proposed placing to raise approximately £8 million

Premaitha (AIM: NIPT) is pleased to announce a placing of approximately 40,000,000 new ordinary shares (the “New Shares”), at a price of 20 pence per share (“Placing Price”) representing approximately 21.3 per cent. of the Company’s existing ordinary share capital to raise approximately £8 million (the “Placing”).

Read more »

Nanobiotix starts Phase I/II clinical trial in liver Metastasis and Hepatocellular Cancer with its lead product NBTXR3

Paris, France – NANOBIOTIX (Euronext: NANO), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, has been authorized to begin a new clinical trial in liver cancers for its lead NanoXray product, NBTXR3.

Read more »

Molecular diagnostics specialist GNA Biosolutions completes EUR 6 million (USD 6.7m) financing round

Munich, Germany - GNA Biosolutions GmbH (GNA), a manufacturer of ultrafast pathogen diagnostic instruments, will receive fresh capital of € 6 million in a series B financing round. Founded in 2010, GNA welcomes new investors Robert Bosch Venture Capital (RBVC), SHS Gesellschaft für Beteiligungsmanagement GmbH, b-to-v Partners, and UnternehmerTUM-Fonds who are investing in its highly promising molecular diagnostics technology. The financing round was led by Robert Bosch Venture Capital. Existing shareholders include Mey Capital Matrix, KfW and the company’s founders.

Read more »

Imperial Innovations: First subject enrolled in Veryan Medical’s MIMICS-2 study

London, UK - Imperial Innovations Group plc (AIM: IVO; ‘the Group’, ‘Innovations’) is pleased to note that portfolio company Veryan Medical (‘Veryan’ or the ‘Company’) has today announced the enrolment of the first subject in its MIMICS-2 study, which has been designed to provide data to support a US Premarket Approval Application (PMA) of the Company’s BioMimics 3D Stent System in the USA. Veryan has already gained a CE Mark enabling sales of its BioMimics 3D™ stent within the European Economic Area (EEA).

Read more »

Imperial Innovations leads GBP3 million investment in Abingdon Health

London, UK - Imperial Innovations Group plc (AIM: IVO; ‘the Group’, ‘Innovations’) has led a £3.0 million investment in portfolio company Abingdon Health Ltd (‘the Company’) alongside existing investors. Innovations committed £2.5m to the round and now holds a 33.7% stake in the Company.

Read more »

CytoTools announces positive intermediate results for the European ulcus cruris trial – seamless transition into an approval-relevant phase III trial with less number of patients

Darmstadt, Germany – The DermaTools Biotech GmbH, a subsidiary of the CytoTools AG, has received the recommendation from the independent „Data and Safety Monitoring Board“ (DSMB), appointed to evaluate the trial, to continue with the current  DermaPro® trial for the ulcus cruris indication. This recommendation was given after the evaluation of the data from the first 80 patients showed an extremely successful healing process.

Read more »

New IONA® test clinical data showcased at the World Congress in Fetal Medicine

Manchester, UK – Premaitha Health plc (“Premaitha” or “the Company”, AIM: NIPT), developer of the IONA® test, the first CE-marked non-invasive prenatal screening test (NIPT), highlights new clinical data on the IONA® test that was presented by leading fetal medicine consultants at the World Congress in Fetal Medicine, Crete on Monday 22 June 2015.

Read more »

Seventure Partners Appoint Two New Members to its Health for Life Capital Fund Investment Committee

Paris, France - Seventure, one of Europe’s leaders in financing innovation, today announced the appointment of Danilo Casadei Massari and Dr Thomas Werner to its Health for Life CapitalTM fund Investment Committee. They are two very experienced figures in the international life science sector with outstanding track records which will strengthen Seventure’s team.

Read more »

ADC Therapeutics Appoints Dr. Chris Martin as Chief Executive Officer

Lausanne, Switzerland and London, UK – ADC Therapeutics Sarl (the Company or ADCT), the oncology research and development company focused on Antibody Drug Conjugates (ADCs) targeting major cancers, today announced the appointment of Dr. Chris Martin as its Chief Executive Officer.

Read more »

Premaitha Health partners with This Is My to offer non-invasive Down’s syndrome screening blood test

Manchester and Leeds, UK – Premaitha Health plc (“Premaitha” or “the Company”, AIM: NIPT), developer of the IONA® test, the first CE-marked test for non-invasive prenatal screening (NIPT), announces that it has signed an agreement with This Is My Limited (“This Is My”), a private ultrasound and pregnancy screening clinic group.

Read more »

NetScientific plc Annual General Meeting

London, UK – NetScientific plc (“NetScientific” or “the Group”, AIM: NSCI), the biomedical and healthcare technology group, is holding its Annual General Meeting (AGM) today at 11am.

Read more »

Trading update

Manchester, UK – Premaitha Health plc ("Premaitha” or “the Company”, AIM: NIPT) announces the following trading update in respect of the financial year ended 31 March 2015.

Read more »

Oxford Gene Technology launches comprehensive SureSeq Myeloid Panel for accurate characterisation of myeloid disorders

Oxford and Cambridge, UK – Oxford Gene Technology (OGT), the molecular genetics company, today announces the launch of the SureSeq™ Myeloid Panel, a highly sensitive next generation sequencing (NGS) panel able to detect mutational changes in 25 genes in one comprehensive assay. The panel replaces the existing procedure of sequential analysis of single genes, to reduce the time and cost associated with identifying myeloproliferative neoplasms (MPNs), a group of diseases that cause abnormal blood cell production.

Read more »

CytoTools AG and existing shareholders strengthen successful subsidiary DermaTools Biotech GmbH with capital increase

Darmstadt, Germany – The shareholders` general meeting of DermaTools Biotech GmbH agreed to a capital increase of approximately 1.3 million EUR, with contributions from existing shareholders and the State of Hessen. The decision was submitted to the commercial register. CytoTools AG participates within the framework of its financial remit, keeping its proportionate holding in DermaTools Biotech GmbH almost constant. CytoTools AG and all the other existing shareholders support DermaTools’ ongoing European trials with this comprehensive strengthening of liquidity and it will provide the means to continue preparations for the ulcus cruris trial in the USA, as well as the initiation of further clinical trials.

Read more »

Vascular Flow Technologies announces collaboration with the Society for Vascular Surgery® (SVS) Patient Safety Organization (PSO) to conduct a new post market observational registry of Spiral Laminar Flow™ AV graft for use in haemodialysis access

Dundee, UK – Vascular Flow Technologies, the medical device company using proprietary Spiral Laminar Flow (SLF™) technology to replicate natural blood flow for enhanced patient outcomes, today announced a new observational registry for Spiral Flow™ arteriovenous (AV) grafts in haemodialysis access that will be conducted by the Society for Vascular Surgery Patient Safety Organization (SVS PSO) as part of their ongoing Vascular Quality Initiative® (VQI). The VQI is designed to improve vascular health care and provides an opportunity for individual providers, hospitals, and regional quality improvement groups to collect and analyze clinical data in an effort to improve patient care.

Read more »

MOF Technologies presents improved natural gas storage data at major industry conference, L-NGV

Belfast, Northern Ireland – MOF Technologies, developer of a novel technique for the synthesis of MOFs (Metal Organic Frameworks), is presenting at the 2015 L-NGV Conference in San Diego (USA) from 17-20 June 2015. The conference focuses on natural gas and other clean fuels for many applications including powering vehicles.

Read more »

Evaluate Ltd.: Pharma R&D Pipeline Value Jumps 18 Percent to $493 Billion, Drug Sales Forecast to Grow Nearly Five Percent Annually

LONDON, BOSTON, TOKYO, PHILADELPHIA -  Emerging therapeutic categories and a string of breakthrough drug approvals are powering key drug sales across the US and Europe, fueling a projected 5 percent increase in global prescription sales over the next five years according to the “EvaluatePharma World Preview 2015, Outlook to 2020” report from life science market intelligence firm Evaluate Ltd. With the FDA approving an unprecedented 50 drugs in 2014, eight of which are forecast to have sales of more than $1 billion five years after launch, sustained R&D productivity may finally be within reach.

Read more »

Marks & Clerk: Antibiotics research risks another lost decade while rare diseases research steams ahead, global patent study reveals

London, UK / Philadelphia, PA, USA – The antibiotics market is at risk of losing another decade to inadequate levels of research and innovation, according to international intellectual property firm Marks & Clerk’s new report From rare to routine – medicines for rare diseases, vaccines and antibiotics, released today at the BIO International Convention 2015 in Philadelphia, USA. Research highlights the striking difference between research levels into rare diseases, vaccines and antibiotics across the globe.

Read more »

Global Bioenergies: Invest Securities Initiates ALGBE Stock Research Coverage With A Buy Recommendation

Evry, France – Invest Securities initiates coverage of Global Bioenergies’ stock (Alternext Paris: ALGBE) with a €50.6 objective.

Read more »

Clinical and performance data from the IONA® test to be presented at the World Congress in Fetal Medicine, Crete

Manchester, UK – Premaitha Health plc (“Premaitha”, AIM: NIPT) is pleased to announce that two leading fetal medicine consultants will be presenting clinical and performance data for the IONA® test at the World Congress in Fetal Medicine from 21 -25 June 2015 in Crete.

Read more »

Instinctif Partners congratulates Andrew Ward on winning the “Mediscience Commentator of the Year” Award

London, UK: Instinctif Partners is pleased to congratulate Andrew Ward of the Financial Times for winning the “Mediscience Commentator of the Year” award at the European Mediscience Awards on 11th June 2015, in recognition of his clear and concise commentary on the Life Sciences Sector.

Read more »

New 1.4 Million Euro Financing for Global Bioenergies

Evry, France - Global Bioenergies obtains new 1.4 million euro financing from Bpifrance on the Isobutene program.

Read more »

e-Therapeutics: Annual General Meeting

Oxford and Newcastle, UK – e-Therapeutics plc (AIM: ETX), the drug discovery and development company, is holding its Annual General Meeting (AGM) today at 10.30am. Ahead of this meeting, the acting Chairman and CEO, Professor Malcolm Young, will provide the following comments:

Read more »

Nanobiotix reports positive preliminary results in Head and Neck cancer Phase I/II clinical trial with NBTXR3

Paris, France – NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces positive preliminary safety results for its lead NanoXray product NBTXR3, in its head and neck cancer Phase I/II clinical trial.

Read more »

Clinical Network Services (CNS) voted Australia’s Favourite CRO 2015

Brisbane, Australia - Clinical Network Services (CNS), an integrated service group focused on clinical product development and headquartered in Australia with offices in New Zealand, the UK and the USA, has announced that it has been voted as Australia’s favourite CRO for 2015 by the foremost membership and professional development association, ARCS Australia Ltd.

Read more »

WISE S.r.l. raises EUR 3 million for clinical development of novel neuromodulation implants for spinal cord stimulation

Milan, Italy and Berlin, Germany - WISE Srl, a medical device company developing next-generation implantable neuromodulation leads announces today the closing of a EUR 3 million series A financing round, led by Principia SGR, an Italian Venture Capital firm. Existing investors High-Tech Gründerfonds, Atlante Seed and b-to-v Partners joined the round alongside with three new investors Atlante Ventures, F3F and Antares.

Read more »

AmpliPhi to Present New Data on Biological Activity of Nebulized Anti-Pseudomonal Bacteriophage

San Diego and Richmond, VA, USA, Ljubljana, Slovenia, and Sydney, Australia – AmpliPhi BioSciences Corporation (OTCQB: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, today announced that new data on the activity of P. aeruginosa bacteriophages after exposure to nebulizer systems applicable for use in future clinical trials will be presented at the European Cystic Fibrosis Conference, taking place in Brussels, Belgium from June 10-13.

Read more »

Premaitha Health: Directorate Change

Manchester, UK: Premaitha Health plc (“Premaitha” or “the Company”; AIM: NIPT) announces the appointment of Barry Hextall, CGMA, MBA, CertIOD as Chief Financial Officer to the Board with immediate effect, replacing Mark Collingbourne.

Read more »

AmpliPhi’s Bacteriophage Manufacturing Facility Receives cGMP Certification

San Diego and Richmond, VA, USA, Ljubljana, Slovenia, and Sydney, Australia – AmpliPhi BioSciences Corporation. (OTCQB: APHB), a global leader in developing bacteriophage-based antibacterial therapies to treat drug resistant infections, announced today that its  production facility in Ljubljana, Slovenia, was cleared by JAZMP, the Agency of the Republic of Slovenia for Medicinal Products and Medical Devices, to manufacture bacteriophages under current Good Manufacturing Practices (cGMP) standards. AmpliPhi will produce Staphylococcus aureus and Pseudomonas aeruginosa bacteriophages to be used in planned human clinical trials.

Read more »

Dezima Pharma’s CETP Inhibitor, TA-8995, Phase 2b (TULIP) Study Results Published in The Lancet

Naarden, The Netherlands, – Dezima Pharma (‘Dezima’), the biotechnology company developing innovative drugs in the field of dyslipidemia, today announced the publication of the phase 2b TULIP study results with its CETP inhibitor, TA-8995, in the Lancet.

Read more »

Innovations leads £6m Series A funding round in Auspherix

London, UK - Imperial Innovations Group plc (AIM: IVO, ‘the Group’, ‘Innovations’) has led a £6m Series A funding round in Auspherix Limited (UK) (“Auspherix” or “the Company”), an early-stage anti-infectives company originated in Sydney, Australia, that is establishing operations on the Stevenage Bioscience Catalyst site just outside of London. Innovations has committed £3m into the Company alongside founding investor Australia’s Medical Research Commercialisation Fund (MRCF). Innovations now holds a 27.5% stake in the company.

Read more »

Auspherix Raises £6Million to Progress its Novel Antibiotics and Establishes UK Operations

Stevenage, UK – In the race to develop new antibiotics with completely new modes of action that might address the growing threat posed by antimicrobial resistance, Auspherix Limited (UK), an early stage anti-infectives company originated in Sydney Australia, has raised £6 million in a Series A venture financing, and is establishing operations on the Stevenage Bioscience Catalyst site just outside of London, UK. New investor Imperial Innovations plc (AIM IVO) led the round alongside Australian founding investor the Medical Research Commercialisation Fund (MRCF).

Read more »

Evaluate Ltd and AdverseEvents, Inc. Team Up to Create New Insight on FDA Adverse Event Reporting

LONDON, BOSTON, TOKYO - Life science market intelligence firm, Evaluate Ltd, has partnered with AdverseEvents, Inc. (AEI), a leading healthcare informatics company focused on drug safety data, to fill a critical gap in commercial insight by enabling detailed FDA post-approval drug safety analysis.

Read more »

First Data from NOXXON’s NOX-H94 (Lexaptepid Pegol) Clinical Trial in ESA-Hyporesponsive Dialysis Patients Reported at ERA-EDTA Conference

Berlin, Germany and Boston, USA - NOXXON Pharma announced that results from Part 1 of its two-part Phase 2a trial of the anti-hepcidin Spiegelmer® NOX-H94 in erythropoiesis-stimulating agent (ESA)-hyporesponsive dialysis patients were reported at the 52nd annual meeting of the European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) conference in London today. This trial is investigating the tolerability, pharmacokinetics, iron mobilization effects and efficacy of NOX-H94 in the treatment of ESA-hyporesponsive anemia.

Read more »

Clinigen Group Named Business of the Year at the European Business Awards

Burton-on-Trent, UK – Clinigen Group plc (‘Clinigen’ or the ‘Group’, AIM: CLIN), the specialty global pharmaceutical company, has been named the winner of the Business of the Year Award with Turnover of €26-150m at Tuesday’s 2014/15 European Business Awards Gala Ceremony in London.

Read more »

PDS Biotechnology reports positive Phase I clinical trial results in proprietary HPV-Cancer Immunotherapy

London, UK – NetScientific (AIM: NSCI) notes that portfolio company, PDS Biotechnology Corp., has announced positive preliminary data showing that its lead cancer immunotherapy treatment, PDS0101, has generated strong T-cell responses in pre-cervical cancer.

Read more »

Clinigen Group Appointed as Specialist Partner to Manage Global Access Program for Clovis Oncology’s Rociletinib for the Treatment of EGFR Mutant Non-Small Cell Lung Cancer

Burton-on-Trent, UK – Clinigen Group plc (‘Clinigen’, AIM: CLIN) today announce the initiation of a global access program in Europe for rociletinib (CO-1686) which is being developed for the treatment of advanced non-small cell lung cancer (NSCLC).

Read more »

DNAe Chairman Professor Chris Toumazou Awarded IEEE Field Medal in Biomedical Engineering for Outstanding Contributions to Biomedical Circuit Technology

London, UK – DNA Electronics (‘DNAe’), the inventors of semiconductor DNA analysis technology and developers of a new, revolutionary point-of-need test for serious blood infections, congratulate its founder and Chairman Professor Chris Toumazou who accepted the Institute of Electrical and Electronics Engineers’ (IEEE) prestigious 2015 Field Medal in Biomedical Engineering last night. Professor Toumazou’s research is dedicated to saving and improving lives through the invention of revolutionary, innovative and disruptive technologies.

Read more »

Cristal Union and Global Bioenergies have formed a joint venture to build and operate France’s first bio-sourced isobutene production plant

Evry and Paris (France) - Cristal Union and Global Bioenergies are announcing today that they have formed IBN-One, a joint venture to build and operate the first plant in France converting renewable resources into isobutene. IBN-One is a société anonyme (limited liability corporation) with share capital of €1,000,000, jointly owned by Cristal Union and Global Bioenergies.

Read more »

e-Therapeutics: Progress in ETS2101 Phase Ib Study

Oxford and Newcastle, UK – e-Therapeutics plc (AIM: ETX) announces today that the first patient has been enrolled into its phase 1b programme for its cancer drug, ETS2101. The first patient received the initial dose on 19 May and will be included in the cohort investigating the safety, tolerability and anti-tumour activity of ETS2101 in patients with newly-diagnosed hepatocellular carcinoma (HCC), in combination with standard of care, sorafenib.

Read more »

AmpliPhi Provides Corporate Update and Reports First Quarter 2015 Financial Results

San Diego and Richmond, VA, USA, Ljubljana, Slovenia, and Sydney, Australia - AmpliPhi BioSciences Corporation (OTCQB: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, today provided a corporate update and announced financial results for the first quarter ended March 31, 2015.

Read more »

Mucosis to Present Data on Intranasal RSV Vaccine SynGEM at Modern Vaccines Adjuvants & Delivery Systems 2015

Groningen, the Netherlands – Mucosis B.V., a clinical stage biotechnology company using a proprietary technology platform to develop next-generation needle-free human vaccines for infectious diseases, announces that its Chief Scientific Officer, Dr. Kees Leenhouts, will present at the Modern Vaccines Adjuvants & Delivery Systems (MVADS) 2015 conference held today at the Leiden University Medical Center in The Netherlands. Dr. Leenhouts will present about the value of Mucosis’ unique and stable prefusion F antigen for use in vaccine delivery, as well as progress with the company’s intranasal respiratory syncytial virus (RSV) vaccine candidate, SynGEM.

Read more »

Imperial Innovations leads GBP25m Series C funding round in PsiOxus

London, UK - Imperial Innovations Group plc (AIM: IVO; ‘the Group’, ‘Innovations’) has led a £25 million Series C funding round in portfolio company PsiOxus Therapeutics (‘PsiOxus’ or ‘the Company’) which is developing innovative oncolytic immuno-oncology treatments for cancer. Innovations has committed £7.0 million to the round alongside current investors Invesco, SROne, Lundbeckfond and Mercia Technologies. In addition, one new investor, Woodford Investment Management, has joined the syndicate.

Read more »

Clinigen Group and Pharming Initiate “HAEi GAP” Global Access Program for RUCONEST®

Burton-on-Trent, UK and Leiden, Netherlands – Clinigen Group plc (“Clinigen” or the “Group”, AIM: CLIN) and Pharming Group N.V. (“Pharming or the Company”, Euronext: PHARM) have entered into an international global access collaboration for HAEi, the International Patient Organization for C1- Inhibitor Deficiencies. The “HAEi GAP” will provide access to RUCONEST® (conestat alfa) to eligible patients with hereditary angioedema (HAE), who currently do not have access to effective medication to treat acute attacks of the disease.

Read more »

OccuRx launched with up to AU$6.5 M in funding

Melbourne, Australia - OccuRx, an Australian biopharmaceutical company developing a new class of drugs to prevent a significant health burden associated with fibrosis, was launched today with up to AU$6.5M in staged tranches of venture capital funding from a consortium including the Medical Research Commercialisation Fund (MRCF), Brandon Capital Partners and Uniseed. At the same time the Company announced that it has successfully established preclinical proof of concept with its lead anti-fibrotic compound in an animal model of ocular inflammation and fibrosis.

Read more »

Global Bioenergies: First Renewable Gasoline Sample Delivered to Audi

Evry (France) and Ingolstadt (Germany) – Global Bioenergies (Alternext Paris: ALGBE) and Audi announce that the first batch of renewable gasoline has been produced. It will be presented to Audi by Global Bioenergies during a press conference to be held in Pomacle on the 21st of May.

Read more »

TopiVert starts Phase I Clinical Trial in Ulcerative Colitis

London, UK - Imperial Innovations Group plc (AIM: IVO or ‘the Group’, ‘Innovations’) notes that portfolio company TopiVert Pharma Ltd (TopiVert or the ‘Company’) today started a Phase I study with its lead compound, TOP1288, in ulcerative colitis (UC) a common inflammatory disease affecting the large bowel.

Read more »

Forbion invests in Autonomic Technologies Europe GmbH

Naarden, Netherlands – Forbion Capital Partners (FCP) today announced their investment in Autonomic Technologies Europe GmbH (ATI GmbH) as part of the USD 38 Million transatlantic series D round raised by Autonomic Technologies Inc. (ATI Inc), developer and manufacturer of PulsanteTM, a microstimulator to treat severe headaches.

Read more »

Global Bioenergies: First Production of Liquid Hydrocarbons from Biological Feedstock Using the Isobutene Process

Evry, France - Global Bioenergies announces today having converted renewable resources into gaseous isobutene, and secondarily into liquid fuels similar to those extracted from oil. This mix of fuels can be compared to light oil, and thus be considered as « renewable oil ».

Read more »

Nanobiotix expands Soft Tissue Sarcoma pivotal clinical trial across Europe and beyond, according to plan

Paris, France – NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces the expansion of the pivotal phase II/III trial for NBTXR3 in Soft Tissue Sarcoma (STS). This trial is the final step before registration (CE mark).

Read more »

NetScientific appoints Dr François R. Martelet as Chief Executive Officer

London, UK –  NetScientific (AIM: NSCI), the biomedical and healthcare technology group, announces the appointment of Dr François R. Martelet as Chief Executive Officer and Board Director.

Read more »

Instinctif Partners congratulates its clients and all short listed nominees for the European Mediscience Awards 2015

London,UK: Instinctif Partners, the business communications consultancy, congratulates all the nominees shortlisted for the European Mediscience Awards 2015, announced today especially those individuals and companies in the category, Commentator of the Year, of which Instinctif Partners is the sponsor.

Read more »

NetScientific invests in wearable digital health company, Neumitra

London, UK – NetScientific (AIM: NSCI), the biomedical and healthcare technology group, today announced its investment in Neumitra, a digital health company, developing wearable devices and smart software applications for the real-time management of stress.

Read more »

Global Bioenergies: First Batch of Isobutene from Renewable Resources Delivered to Arkema

Evry,France - Global Bioenergies (NYSE Alternext Paris: ALGBE) announces the delivery of the first batch of isobutene from renewable resources to Arkema six months ahead of the projected schedule.

Read more »

Themis Bioscience’s Raises up to EUR 10 Million in Series B

Vienna, Austria - Themis Bioscience (‘Themis’), a biotechnology company developing innovative prophylactic vaccines for emerging tropical infections, announced today the first closing of EUR 7 Million in a Series B financing of up to EUR 10 Million, led by new investor Wellington Partners. Existing investors Ventech and Omnes Capital (formerly Crédit Agricole Private Equity) also participated in the round. Dr Regina Hodits, General Partner at Wellington Partners will join Themis’ Board.

Read more »

Premaitha files robust defence with UK’s High Court in response to alleged infringement of NIPT patents

Manchester, UK –  Premaitha Health plc (“Premaitha”, AIM: NIPT) announces that it has filed a robust defence and counterclaim in the High Court of Justice, Chancery Division, Patents Court in the United Kingdom in connection with the patent infringement suit filed on 16 March 2015 by Illumina, Inc. and its wholly-owned subsidiary Verinata Health Inc.

Read more »

AmpliPhi Biosciences Announces M. Scott Salka as New CEO

San Diego and Richmond, VA, USA, Ljubljana, Slovenia, and Sydney, Australia – AmpliPhi BioSciences Corporation (OTCQB: APHB), a global leader in developing bacteriophage-based antibacterial therapies to treat drug resistant infections, today announced that Scott Salka has been appointed as the new CEO. Mr. Salka will replace Interim CEO and Chairman of AmpliPhi, Jeremy Curnock Cook, effective May 18. Mr. Curnock Cook will remain in his role as Chairman.

Read more »

NetScientific forms digital health company with US hospital group, Meridian Health

London,UK - NetScientific (AIM: NSCI), the biomedical and healthcare technology group, has  formed a new digital health sales and marketing subsidiary company, Triventis Health LLC (“Triventis”) in partnership with iMPak Health, LLC (“iMPak”), a wholly owned subsidiary of Meridian Health Hospital Group, New Jersey, USA.

Read more »

Synthon Announces Successful Outcomes from the Open-label extension of the Phase III GATE Study of Synthon’s Glatiramer Acetate

Nijmegen, the Netherlands - Synthon announces that data from the open-label extension of the Phase III GATE study of the Company’s generic glatiramer acetate in patients with relapsing remitting multiple sclerosis (RRMS) demonstrate that efficacy, safety and tolerability were maintained over the entire two-year study period. The data further support the safety of switching from Copaxone® to Synthon’s glatiramer acetate.

Read more »

Global Bioenergies Receives the Tech40 Label From Alternext

Evry (France) – Global Bioenergies (Alternext Paris : ALGBE) has been selected to be part of the new Tech40 label which highlights 40 high-tech companies listed on Alternext. 

Read more »

Imperial Innovations - Autifony Therapeutics recruits first patient into Phase IIa trial for age related hearing loss

London, UK - Imperial Innovations Group plc (AIM: IVO, "Innovations", “the Group”) is pleased to note that portfolio company Autifony Therapeutics (“Autifony” or “the Company”) has today announced that it has recruited the first subject in a Phase IIa study for treatment of age-related hearing loss.

Read more »

Autifony Therapeutics recruits first patient into Phase IIa trial for first-in-class drug to treat Age Related Hearing Loss

London, UK - Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for hearing disorders, today announced that it has recruited the first subject in a Phase IIa study for treatment of Age Related Hearing Loss. This proof of concept study (called CLARITY-1) will explore the potential of AUT00063, Autifony’s first-in-class Kv3 potassium channel modulator, to improve hearing in the elderly by focusing on the discrimination of speech from background noise, which is an area of significant unmet medical need.

Read more »

Clinigen: £225 million Acquisition of Idis and £135 million Vendor Placing

Burton-on-Trent, UK – Clinigen Group plc (“Clinigen”, the “Company” or the “Group”, AIM: CLIN), the specialty global pharmaceutical company, has agreed to acquire Idis Group Holdings Limited (“Idis”), creating the market leader in the ethical unlicensed supply of medicines (“the Acquisition”). Idis is being acquired for an enterprise value of £225.0 million.

Read more »

NOXXON Pharma: Nature Communications Publications on the First X-ray Crystal Structures of Spiegelmers Bound to Protein Targets

Berlin, Germany and Boston, USA - NOXXON Pharma announced today the publication of two new studies in Nature Communications, entitled:

  • Crystal structure of a mirror-image L-RNA aptamer (Spiegelmer) in complex with the natural L-protein target CCL2
  • Structural basis for the targeting of complement anaphylatoxin C5a using a mixed L-RNA/L-DNA aptamer 
Read more »

Intercept Announces New FLINT Trial Data Showing OCA Treatment Increases Fibrosis Resolution and Cirrhosis Prevention in High-Risk NASH Patients

New York - Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept) announced today the availability of additional post-hoc analyses from the Phase 2b FLINT trial of obeticholic acid (OCA) in patients with nonalcoholic steatohepatitis (NASH) at the International Liver Congress 2015, the 50th Annual Meeting of the European Association for the Study of the Liver (EASL), being held in Vienna, Austria, from April 22-26, 2015.

Read more »

Instinctif Partners Life Sciences Team Adds Six New Clients in Q1 2015

London, Manchester, Munich, New York, Sydney, Melbourne: In the first quarter of 2015, the Life Sciences team of international business communications consultancy, Instinctif Partners, had a busy kick-off to the year securing six new clients.

Read more »

Brandon Capital Partners Raises AUD200M New MRCF Fund

Melbourne & Sydney, Australia – Brandon Capital, one of Australia’s leading life science venture capital firms, today announced that it has closed an AU$200Million life science venture capital fund for the Medical Research Commercialisation Fund (MRCF). The new fund (MRCF3) will be Australia’s largest ever life science venture fund.

Read more »

Regenerys® announces pilot study of its Adiposet Service for lipomodelling that will provide safety, confidence and affordability

Sheffield, UK - Regenerys Ltd. (www.regenerys.com), the Sheffield- and Cambridge-based regenerative medicine company announces a pilot study of its Adiposet tissue collection, testing and storage service, which has the potential to reduce the number of general anaesthetic and surgical procedures required by patients undergoing breast reconstruction following cancer surgery.

Read more »

MISSION Therapeutics presents at the annual meeting of American Association for Cancer Research (AACR) the identification of novel inhibitors of the UCHL1 oncogene

Philadelphia, PA, US and Cambridge UK – MISSION Therapeutics, a company focused on the discovery and development of modulators of the deubiquitylating (DUB) enzyme family for the treatment of cancer and other diseases, today presents a poster at AACR entitled “Discovery of highly selective UCHL1 inhibitors with in vivo pre-clinical anti-tumour activity”.

Read more »

Global Bioenergies: Baader Bank Initiates ALGBE Stock Research Coverage with a Buy Recommendation

Evry (France) - Baader Bank initiates coverage of Global Bioenergies’ stock (NYSE Alternext Paris : ALGBE) with a price target of €57.

Read more »

Vascular Flow Technologies: Spiral Flow™ AV graft shows substantial improvement in patency over current standard of care

Dundee, UK – Vascular Flow Technologies (VFT), the medical device company using proprietary Spiral Laminar Flow™ (SLF™) technology to replicate natural blood flow for enhanced patient outcomes, announce today the presentation of independent study results demonstrating substantially better primary patency rates for its Spiral Flow™ arteriovenous (AV) graft than for polytetrafluoroethylene (PTFE) graft.

Read more »

Autifony Therapeutics announces £3.3 million collaboration to progress first-in-class drug for schizophrenia into clinical trials

London, UK – Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for hearing disorders, today announced a £3.3 million collaborative project to progress its new drug, AUT00206 into clinical trials for the treatment of schizophrenia. £2.4 million will come from the Biomedical Catalyst, jointly funded by Innovate UK and the Medical Research Council.

Read more »

Driving Sustainable Agriculture through Improved Qualities in Eucalyptus and Poplar Trees

GERMANTOWN, MD, and SAO PAULO – Intrexon Corporation (NYSE: XON), a leader in synthetic biology, and FuturaGene Group, a wholly owned subsidiary of Suzano Papel e Celulose S.A., the second largest producer of eucalyptus pulp in the world, today announced they have entered into an exclusive collaboration to increase biomass in eucalyptus and poplar trees.  FuturaGene has established itself as a leader in the development of sustainable solutions for global forestry, biofuel and agricultural markets through its proficiency in taking optimal traits from discovery to elite event selection in large scale field trials across multiple geographies as well as obtaining regulatory approval for such traits in tree crops.  This collaboration will utilize Intrexon’s platform to design complex, innovative gene constructs and FuturaGene’s expertise in plant yield enhancement to cultivate improved qualities in eucalyptus, the second most widely used species in the paper and pulp industry, as well as in poplar trees.

Read more »

CytoTools AG: Recruitment of patients now complete for European studies on diabetic foot (DFU) and ulcus cruris (VLU) indications

Darmstadt - All patients needed for the clinical phase III study on the wound healing drug DermaPro® for the diabetic foot (DFU) indication in Europe have now been successfully recruited. For this study, more than 300 patients have been recruited at 36 renowned European diabetics clinics in 7 countries. The three-month treatment period will be followed by an evaluation stage, enabling the study results to be presented in the second half of 2015.

Read more »

Nanobiotix: 2014 Annual Results

Paris, France – NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces today its audited consolidated results for the fiscal year ended December 31, 2014.

Read more »

Rentschler Biotechnologie expands European manufacturing capabilities with GE Healthcare Life Sciences bioprocess technologies

Chalfont St Giles, UK and Laupheim, Germany - GE Healthcare Life Sciences, a provider of tools, technologies and services to the biopharmaceutical manufacturing industry, and Rentschler Biotechnologie GmbH, a leading contract manufacturing and development organization (CDMO) for biopharmaceuticals, announced today a joint celebration to mark the handover of GE Healthcare’s 1000th ÄKTAprocess™ and the expansion of Rentschler’s biopharmaceutical manufacturing capabilities in Laupheim, Germany. ÄKTAprocess, GE’s automated process and manufacturing scale chromatography system, has gone into operation as part of Rentschler’s recently expanded single-use manufacturing suite. GE biomanufacturing technologies such as the XDR 2000L bioreactor, the associated seed trains of 50, 200 and 500 L as well as the new ÄKTAprocess play a key role in Rentschler’s new single-use manufacturing line.

Read more »

FuturaGene’s eucalyptus is approved for commercial use in Brazil

São Paulo – The Brazilian National Technical Commission on Biosafety (CTNBio) today approved the commercial use of the yield enhanced eucalyptus developed by FuturaGene, a wholly owned subsidiary of Suzano Pulp and Paper. Field experiments conducted since 2006 at various locations in Brazil have demonstrated an approximate 20% increase in yield compared to its equivalent conventional variety.

Read more »

GLOBAL BIOENERGIES REPORTS 2014 FINANCIAL RESULTS

Evry (France) – Global Bioenergies (Alternext Paris: ALGBE) published financial statements today for the fiscal year ending December 31st, 2014. The financial results were approved by the Board of Directors on April 8th, 2015.

Read more »

Clinigen Group Recognized for Service and Commitment to People Development

Burton-on-Trent, UK – Clinigen Group plc (‘Clinigen’ or the ‘Group’, AIM: CLIN) today announces two important milestones in its pursuit of world-class customer service and commitment to developing the best people.

Read more »

Clinigen Group - Succession Planning - Board Change

Burton-on-Trent, UK – 1 April 2015 – Clinigen Group plc (‘Clinigen’ or the ‘Group’, AIM: CLIN), the specialty global pharmaceutical company, today announces plans for the orderly succession of the role of Chief Financial Officer.

Read more »

Oxford Gene Technology signs license with Wellcome Trust Sanger Institute for access to Deciphering Developmental Disorders data

Oxford and Cambridge, UK – 1 April 2015 – Oxford Gene Technology (OGT), the molecular genetics company, today announced that it has signed a license agreement with the Wellcome Trust Sanger Institute for access to data from the Deciphering Developmental Disorders (DDD) study.

Read more »

AmpliPhi Granted European Patent for Bacteriophage Therapy to Fight Biofilm-related Bacterial Infections

Richmond, VA, USA, Ljubljana, Slovenia, and Sydney, Australia – AmpliPhi BioSciences Corporation. (OTCBB: APHB), the global leader in developing bacteriophage-based antibacterial therapies to treat drug resistant infections, today announced that the European Patent Office (EPO) has granted European patent no. EP 2570130, “Bacteriophage-containing Therapeutic Agents”. Three related patents have been issued in the United States (U.S. Patent Nos. 7,807,149, 8,105,579, and 8,388,946), the earliest of which was previously granted in 2010.

Read more »

PREMAITHA HEALTH: Centrum Badan DNA partners with Premaitha Health to offer the IONA test in Poland

Manchester, UK and Warsaw, Poland – Premaitha Health plc (“Premaitha”, AIM: NIPT) and Centrum Badan DNA group in Poland (“Centrum Badan”) announce today a collaboration agreement for Premaitha to supply its CE-marked in vitro diagnostic (IVD) the IONA test for non-invasive prenatal screening (NIPT) to Centrum Badan.

Read more »

E-THERAPEUTICS PLC: Four Clinical Trials and Striking Results from Discovery Engine

 e-Therapeutics plc (AIM: ETX), the drug discovery and development company, today announces its full year results for the year ended 31 January 2015.

Read more »

DySIS Colposcopy named within UK National Colposcopy Guidelines by the NHS Cervical Screening Programme

Edinburgh, UK – 30 March 2015 − DySIS Medical Ltd., announced today that its DySIS Colposcope has been recognised as an approved advanced technology by the NHS Cervical Screening Programme (NHSCSP) in the latest UK National Colposcopy Guidelines (Document 20).

Read more »

Alesi Surgical secures £2.1m funding to drive commercialisation of Ultravision

Cardiff, UK, 30 March 2015 - Alesi Surgical (formerly Asalus Medical Instruments Limited) announced today that it has secured additional funding of £2.1 million to drive the further commercialisation of its lead product, Ultravision, which was developed from concept to CE-marked device with backing from IP Group and Finance Wales.

Read more »

Strong underlying performance and progress across maturing portfolio

Portfolio developments
• £22.4 million invested in 13 portfolio companies (H12014: £17.8 million in 17) including:
        o £7.5 million first tranche invested as part of £50.0 million funding round for Cell Medica
        o £2.7 million first tranche invested as part of £18.0million funding round for Veryan
• Completed the sale of a software business realising £4.1 million, representing an IRR of 65% and a 2.4x multiple on cash invested in an investment made in January 2013
• One new company added to unquoted investment portfolio with an investment of £0.8 million

Read more »

Mucosis to Present on Intranasal Respiratory Syncytial Virus Vaccine Candidate SynGEM® at BioCapital Europe

Groningen, the Netherlands – Mucosis B.V., a clinical stage biotechnology company using a proprietary technology platform to develop next-generation needle-free human vaccines for infectious diseases, announces today that CEO, Tom Johnston, will present a Company update at BioCapital Europe in Amsterdam on March 26.

Read more »

NetScientific Full Year results: Significant Progress in Core Portfolio Companies Wanda Health and Vortex BioSciences

London, UK – NetScientific (AIM: NSCI), the biomedical and healthcare group, announces its results for the year ended 31 December 2014.

Read more »

Leading London NHS trust teams up with Premaitha Health to create the UK’s first Centre of Excellence for non-invasive prenatal screening

Manchester, UK and London, UK – Premaitha Health plc (“Premaitha”, AIM: NIPT) and St George’s University Hospitals NHS Foundation Trust (“St George’s” or “the Trust”) announce today that Premaitha has been awarded the contract to provide its non-invasive prenatal test (NIPT), the IONA® test, to St George’s following a competitive tender process.

Read more »

Pharma and Biotech M&A Deals Reached Record $212 Billion in 2014

LONDON, BOSTON, TOKYO  — Despite a slight wobble in the spring, the pharma and biotech sector came back stronger than ever in 2014, racking up a record-breaking $212 billion in M&A transactions. The feel good factor also extended to IPOs. Largely fueled by investor appetite for immunotherapy, 2014 boasted 87 flotations, raising a combined $6.3 billion, one of the best hauls since the genomic bubble of 2000.

Read more »

Next Closing Brings Seventure Partners’ Health for Life Capital Investment Vehicle to €100m

Paris, France  – Seventure, one of Europe’s leaders in financing innovation, has received further investment in its Health for Life Capital™, the largest fund worldwide that focusses primarily on microbiome-based biotech and nutrition innovations. The fund raising has attracted both financial investors, strategic investors and serial entrepreneurs.

Read more »

Imperial Innovations' Cell Medica granted Orphan Drug designation for novel cellular therapy and treats first lymphoma patient in CITADEL Phase II trial

Imperial Innovations Group plc (AIM: IVO, "Innovations", “the Group”) is pleased to note that its portfolio company Cell Medica (“the Company”) has today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to the Company’s lead cancer immunotherapy product CMD-003. The designation was granted for the treatment of Epstein-Barr Virus (EBV) positive non-Hodgkin lymphomas.  Additionally, the Company announced the treatment of the first patient in its CITADEL Phase II trial. This is a clinical study is investigating the safety and efficacy of CMD-003 for the treatment of aggressive extranodal NK/T cell lymphoma (ENKTCL) in patients whose treatment with other therapies has proved unsuccessful. The patient was treated at Dana-Farber Cancer Center in Boston, Massachusetts.

Read more »

Cell Medica granted Orphan Drug designation for novel cellular therapy; Treats first lymphoma patient in Phase II trial

London, UK - Cell Medica, a leading cellular immunotherapy company, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to the company’s cancer immunotherapy treatment, referred to as CMD-003, under development for Epstein-Barr Virus (EBV) positive non-Hodgkin lymphomas. Additionally, the company announced the treatment of the first patient in the CITADEL Phase II clinical trial investigating the safety and efficacy of CMD-003 for the treatment of aggressive extranodal NK/T cell lymphoma (ENKTCL) in patients who have failed previous therapies. The patient was treated at the Dana-Farber Cancer Institute in Boston, MA under the care of Dr Eric Jacobsen.

Read more »

Nanobiotix appoints its Manufacturing Partner, CordenPharma : another step towards commercialization

Paris, France – NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces it has appointed CordenPharma as its manufacturing partner. The opening of a new manufacturing line and the scaling up of production is an important step in NBTXR3’s route to commercialization.

Read more »

Polyphor appoints Michael Altorfer as new CEO and strengthens executive management team

Allschwil, Switzerland - Polyphor Ltd, a privately held Swiss pharmaceutical company specializing in the discovery and development of macrocycle drugs, today announced the appointment of Michael Altorfer as new CEO and successor of Jean-Pierre Obrecht as of March 31, 2015. Jean-Pierre Obrecht will continue to support the company in his role as a Member of the Board of Directors.

Read more »

Premaitha Health: Notice of Patent Infringement Proceedings

Manchester, UK Premaitha Health plc (“Premaitha” AIM: NIPT) an innovative molecular diagnostics company employing the latest advances in DNA analysis technology to develop tests for non-invasive prenatal testing (NIPT) has been informed that Illumina, Inc. and its wholly-owned subsidiary Verinata Health Inc., have filed a patent infringement suit against Premaitha in the High Court of Justice, Chancery Division, Patents Court in the United Kingdom. The patents asserted are European Patent (UK) 0 994 963 B2 and European Patent (UK) 1 981 995 B1.

Read more »

ADC Therapeutics Submits its First IND For a Novel Antibody Drug Conjugate Against Lymphomas

Lausanne, Switzerland and London, UK - ADC Therapeutics Sarl (the “Company”), the oncology drug development company focused on Antibody Drug Conjugates (ADCs), today announced that it has filed an Investigational New Drug application (IND) with the US Food and Drug Administration as it moves its pipeline into clinical development. The IND is for a Phase I clinical trial for ADCT-301, a novel antibody drug conjugate targeting CD25, a cell-surface antigen, which is over-expressed in many patients with lymphomas.

Read more »

MISSION Appoints Paul Wallace as Chief Business Officer

Cambridge, UK - MISSION Therapeutics, a company focused on the discovery and development of modulators of the deubiquitylating (DUB) enzyme family for the treatment of cancer and other diseases, announces the appointment of Paul Wallace PhD as Chief Business Officer.

Read more »

Premaitha Health and Esperite NV Sign a Collaboration Agreement for NIPT Provision in Europe

Manchester, UK and Zutphen, the Netherlands –  Premaitha Health plc (“Premaitha”, AIM: NIPT) and Esperite NV (“Esperite”, AMS: ESP, Zutphen, the Netherlands) today announce the signing of an agreement under which Genoma SA (“Genoma”, Geneva, Switzerland), the fully owned subsidiary of Esperite will have the right to use Premaitha’s CE-IVD IONA® test for its non-invasive prenatal testing (NIPT) service called TRANQUILITY®. Access to Premaitha’s test will allow Genoma to apply the CE-IVD marking to its NIPT for trisomies 21, 18 and 13.

Read more »

AmpliPhi BioSciences Corporation Announces $13 Million Financing

Richmond, VA, USA, Ljubljana, Slovenia, and Sydney, Australia – AmpliPhi BioSciences Corporation, (OTCQB: APHB), a global leader in bacteriophage-based antibacterial therapies to treat drug resistant infections, announced today that it has entered into definitive purchase agreements of common stock and warrants with a group of institutional accredited investors, including both existing and new investors, as well as with its strategic alliance partner Intrexon (NYSE: XON), to raise approximately $13,000,000 in a private placement financing. Pursuant to the purchase agreements, the Company will issue an aggregate of 78,787,880 shares of the Company's common stock at a price per share of $0.165, as well as the sale and issuance of warrants to purchase 0.25 shares of common stock for each share of common stock per warrant share. The warrants, which represent the right to purchase an aggregate of 19,696,971 shares of common stock, expire in March 2020 and will be exercisable at a price of $0.215 per share. The warrants will be exercisable beginning on the later of (i) the first anniversary of the date of issuance and (ii) the date AmpliPhi effects a reverse stock split or increases the number of authorized shares of common stock, in either case in an amount sufficient to permit the exercise in full of the warrants issued in this offering. If the reverse stock split or share increase occurs before the first anniversary, the warrants will be exercisable at that time.

Read more »

Oxford Gene Technology Awarded £1.2m Genomics England Contract

Oxford and Cambridge, UK – Oxford Gene Technology (OGT), the molecular genetics company, today announced it has been awarded a £1.2m phase two Small Business Research Initiative (SBRI) Healthcare contract. The contract is to develop Next Generation Sequencing (NGS) analysis software, following the successful completion of phase one and an evaluation by Genomics England, UK Department of Health and Innovate UK.

Read more »

Clinigen Group Extends Exclusive Foscavir® US Distribution Agreement with Hospira to 2019

Burton on Trent, UK –  Clinigen Group plc (‘Clinigen’ or the ‘Group’, AIM: CLIN) today announces the extension and renegotiation of the exclusive license and distribution agreement with Hospira, Inc (‘Hospira’) for its anti-viral product Foscavir® (foscarnet sodium) in the US.  This is expected to be beneficial to both parties.

Read more »

Evaluate Ltd.: Five Year Peak Sales Forecast of Newly Reimbursed Drugs in Japan Surges to $34bn

LONDON, BOSTON, TOKYO - Despite depreciation of the Japanese Yen, the overall output of the Japanese drug industry measured by expected peak sales potential of newly National Health Insurance (NHI) reimbursed drugs surged to $34 billion between 2010-2014, up from $16.9 billion during 2005-2009 according to Evaluate’s new report “Japan Sales, Volume, Pricing 2015.”

Read more »

e-Therapeutics plc: Notification of Full Year Results Date

Oxford and Newcastle, UK – e-Therapeutics plc (AIM: ETX), the drug discovery and development company, will announce its full year results for the period ended 31 January 2015 on Tuesday, 31 March 2015.

Read more »

SynAffix BV to Present Latest Advancement in Antibody--Drug Conjugate Technology at the 9th Annual BIO Europe Spring Conference in Paris

THE NETHERLANDS - SynAffix BV, a biotechnology company exclusively focused on the development of industry-leading antibody-drug conjugate (ADC) technology platforms, today announced that it will present the new and underlying technologies used to generate enhanced ADCs at the 9th Annual BIO Europe Spring Conference on March 10 in Paris.

Read more »

Instinctif Partners Continues its Sponsorship of the European Mediscience Awards Event for the 7th year

London, UK: Instinctif Partners (formerly College Hill) is pleased to confirm that it is the sponsor for the "Mediscience Commentator of the Year" at the European Mediscience awards for the 7th year running. The event, to be held in London on 11 June 2015 celebrates significant achievements in the healthcare and life sciences industry for both quoted and private companies.  Nominations for the Awards are now open.

Read more »

Vascular Flow Technologies signs deal with Vascutek to strengthen presence in Europe

Dundee, UK – Vascular Flow Technologies, the medical device company using proprietary Spiral Laminar Flow (SLF™) technology to replicate natural blood flow for enhanced patient outcomes, has appointed Vascutek as an exclusive regional distributor in France, Germany, Austria and Switzerland.

Read more »

GLOBAL BIOENERGIES reports first isobutene production from waste biomass

Evry, France – Global Bioenergies (Alternext Paris – ALGBE) announces today having produced “second generation” isobutene, in a push to diversify accessible feedstock towards cheaper resources.

Read more »

Half year revenues up 17% to £72.6m, underlying EBITDA up 8% to £13.5m

Burton-on-Trent, UK – Clinigen Group plc (AIM: CLIN, Clinigen or the Group), the global specialty pharmaceuticals and pharmaceutical services business, has today published its half year results for the six months ended 31 December 2014.

Read more »

Themis Bioscience’s Chikungunya Vaccine Study Results Published in The Lancet Infectious Diseases

Vienna, Austria - Themis Bioscience (‘Themis’), a biotechnology company developing innovative prophylactic vaccines for emerging tropical infections, and the Institut Pasteur, an international biomedical research center based in Paris (France) today announced the publication of the phase I study results for a recombinant measles-virus-based chikungunya vaccine (MV-CHIK) in The Lancet Infectious Diseases. The study was performed in collaboration with the Department of Clinical Pharmacology at the Medical University of Vienna and the Viral Diseases Branch of the Walter Reed Army Institute of Research (WRAIR) in the USA.
 

Read more »

Nanobiotix 2014 Q4 and annual revenues

Paris, France – NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205) – a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announces its revenues for Q4 and the annual revenues for the year ended December 31, 2014. 

Read more »

Clinigen Group Signs Distribution Agreement with MSD UK for Clinical Trial Supply Services

Burton-on-Trent, UK – Clinigen Group plc (‘Clinigen’ or the ‘Group’, AIM: CLIN) today announces that its Clinical Trials Supply business (Clinigen CTS) has entered into an agreement with Merck Sharp & Dohme Limited (‘MSD’), to distribute their human health products for use in clinical trials carried out in Europe. This agreement now represents the fourth arrangement Clinigen CTS has with manufacturers to distribute products.

Read more »

NetScientific: Appointment to the Board

NetScientific (AIM:NSCI), the biomedical and healthcare technology group is pleased to announce that Jonathan Paisner will join the Board  with immediate effect as a non-executive director.

Read more »

Orca Pharmaceuticals and AstraZeneca Announce Development Partnership to Identify Best-in-Class RORy Inhibitors to Treat Autoimmune Disease

OXFORD – Orca Pharmaceuticals, a UK based biopharmaceutical company, and AstraZeneca today announced a three year collaboration to develop inhibitors of retinoic acid–related orphan nuclear receptor gamma (RORy). Inhibitors of this receptor are believed to have potential against a wide range of autoimmune diseases for which there is currently no safe, orally available and effective treatment.

Read more »

Intercept Announces Promotion of Lisa Bright to Chief Commercial & Corporate Affairs Officer

NEW YORK - Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel bile acid therapeutics to treat chronic liver diseases, today announced that Lisa Bright has been promoted to the newly-created position of Chief Commercial and Corporate Affairs Officer. Ms. Bright joined Intercept last year from Gilead Sciences where her leadership of the European launch of Sovaldi for the treatment of chronic hepatitis C contributed to the most successful product launch in pharmaceutical history.

Read more »

Professor Robert Langer joins Nanobiotix as Scientific Advisor

Paris, France – NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announced that Professor Robert Langer, Institute Professor at the Massachusetts Institute of Technology (MIT), has become Scientific Advisor to Nanobiotix.

Read more »

GNA Biosolutions Leads Consortium for Ultra-Fast Detection of Ebola

Munich, Germany - GNA Biosolutions GmbH (‘GNA’), a company developing ultra-fast diagnostic instruments for human pathogens, announced today the start of the FILODIAG (Filovirus Diagnostics) project for developing an ultra-fast Ebola detection system based on GNA’s novel Laser PCR technology.

Read more »

Cell Medica begins commercial production at newly licensed cell therapy manufacturing facility in Germany

London, UK - Cell Medica, a leading cellular immunotherapy company, today announced the start of commercial cell therapy manufacturing at its facility at the Max-Delbrück-Center of Molecular Medicine in Berlin-Buch (Germany). The first product has been successfully manufactured and delivered for use in the patient.

Read more »

Imperial Innovation's Cell Medica announces start of commercial cell therapy manufacture

London, UK - Imperial Innovations Group plc (AIM: IVO, "Innovations", “the Group”) is pleased to note that its portfolio company Cell Medica (“the Company”) has today announced the start of commercial cell therapy manufacturing at its facility at the Max-Delbrück-Center of Molecular Medicine in Berlin-Buch (Germany). The first product has been successfully manufactured and delivered for use in the patient.

Read more »

Clinigen Group Adds New Named Patient Program to Global Access Portfolio

Burton-on-Trent, UK – Clinigen Group plc (‘Clinigen’ or the ‘Group’, AIM:CLIN) announces the latest program to be managed by Clinigen Global Access Programs (Clinigen GAP). The program will provide access to Raptor Pharmaceuticals Corp.’s PROCYSBI® (cysteamine bitartrate) for individual patients with nephropathic cystinosis. Through the program PROCYSBI® will be available worldwide, except for the USA where the drug is already commercially available, LATAM and a small number of European territories.

Read more »

Clinigen: Notification of Half Year Results Date

Burton-on-Trent, UK – Clinigen Group plc (AIM: CLIN), the global specialty pharmaceuticals and services company, will announce its half year results for the six months ended 31 December 2014 on Tuesday, 3 March 2015.

Read more »

MerLion announces FDA approval of finafloxacin otic suspension

Singapore - MerLion Pharmaceuticals (MerLion), a biopharmaceutical company headquartered in Singapore with clinical development operations in Berlin, Germany, today announced that an otic suspension of finafloxacin has been approved by the FDA to treat acute otitis externa, commonly known as “swimmer’s ear”, caused by Pseudomonas aeruginosa and Staphylococcus aureus. Finafloxacin was licensed by MerLion to a major North American partner in 2010 for use in North America for otic (ear) infections.

Read more »

Clinigen Appointed by AstraZeneca to Manage International Global Access Program for New Combination Antibiotic, CAZ-AVI

Burton-on-Trent, UK – Clinigen Group plc (‘Clinigen’ or the ‘Group’, AIM: CLIN) announced today the initiation of an international global access program for AstraZeneca’s investigational antibiotic, CAZ-AVI (ceftazidame-avibactam), through its specialist Clinigen GAP division.

Read more »

Vaxxas Raises AUD 25 Million (USD 20 Million) in Series B Financing to Accelerate Commercialization of Novel Vaccine Platform

Cambridge, Mass., USA, and Brisbane, Queensland, Australia - Vaxxas, a biotechnology company commercializing a novel vaccination platform, today announced it has secured equity funding of A$25 million [US$20 million] from new and existing investors.  These funds represent the first closing of a Series B venture financing round, the proceeds from which will be used to advance a series of clinical programs and develop a pipeline of new vaccine products for major diseases using Vaxxas’ patented Nanopatch platform.  This new round of financing brings the total capital raised by Vaxxas to A$40 million (US$33 million).

Read more »

Premaitha Health Launches the IONA® test, the First Ever CE-marked NIPT Product for Pregnant Women

Manchester, UK – Premaitha Health plc (“Premaitha” or the “Company”, AIM: NIPT), an innovative molecular diagnostics company employing the latest advances in DNA analysis technology to develop tests for non-invasive prenatal testing (NIPT) today announces receipt of CE mark approval and launch of the IONA® test, the first CE-marked in vitro diagnostic (IVD) product for NIPT. The CE Mark means that the IONA® test has met the stringent quality standards set down by the In Vitro Diagnostic Medical Device Directive (98/79/EC). Premaitha is the only company authorised by the European Regulatory agencies to sell a product to allow a laboratory to offer an NIPT service.

Read more »

GLOBAL BIOENERGIES: First milestone hit in BioMA+ project

Evry, France – GLOBAL BIOENERGIES (Alternext Paris: ALGBE) announces having reached the first milestone of the BioMA+ project which is financed by the French “Investissements d’Avenir” State program. The project aims at developing a renewable value chain to methacrylic acid, a key constituent of acrylic paints. Achieving this first milestone result unlocks a €1.7m payment.

Read more »

Vascular Flow Technologies announces strengthening of US team with the appointment of Dr Barbara Bunger as Chief Clinical Officer

Dundee, UK – Vascular Flow Technologies, the medical device company using proprietary Spiral Laminar Flow (SLF™) technology to replicate natural blood flow for enhanced patient outcomes, today announces the appointment of Dr Barbara Bunger as Chief Clinical Officer.

Read more »

PharmaVentures Termsheet

The old pharmaceutical industry business model of the $1bn “Blockbuster” drug is rapidly being supplemented by more personalised approaches to medicine, with reimbursement being matched to effectiveness vs. a trial and error approach. Within this new environment for “Microbusters”, orphan drugs that treat rare diseases, i.e. drugs with small patient populations (in the UK this is defined as less than 200,000 patients) but that can command very high prices (up to £300,000 per patient per year) have become popular.

Read more »

Premaitha Health Receives ISO 13485:2003 Certification and Meets Annex IV of the In Vitro Diagnostic Medical Device Directive

Manchester, UK – Premaitha Health plc (”Premaitha” or the “Company”, AIM: NIPT), an innovative molecular diagnostics company employing the latest advances in DNA analysis technology to develop tests for non-invasive prenatal testing (NIPT) today announces that it has met two key requirements for obtaining a CE-mark for its IONA® test: ISO 13485:2003 certification and a successful audit of Annex IV of the In Vitro Diagnostic Medical Device Directive (98/79/EC).

Read more »

Forbion Capital Partners leads CAD 13.5 Million (EUR 9.6 million) Series B financing round for enGene Inc.

Naarden, The Netherlands - Forbion Capital Partners, a Dutch life-sciences venture capital firm, announces today that it has led the closing of a CAD 13.5 million (EUR 9.6 million) series B financing round for enGene, Inc. with a syndicate of leading life-science investors. Sander van Deventer from Forbion Capital Partners has joined the enGene Board of Directors.

Read more »

Not for the Faint of CAR-T: The CAR-T Therapy Landscape in 2015

LONDON, BOSTON, TOKYO — The market interest surrounding anti-tumour CAR-T therapies was one of the defining themes of 2014 and investor enthusiasm for the area is unlikely to abate in 2015. But there may be hidden dangers for those seeking to make big returns, according to a new reportpublished by EP Vantage, the editorial arm of market intelligence firm Evaluate Ltd.

Read more »

Vascular Flow Technologies announces new Haemodialysis Access study funded by Scottish Enterprise Grant

Dundee, UK – Vascular Flow Technologies, the medical device company using proprietary Spiral Laminar Flow™ (SLF™) technology to replicate natural blood flow for enhanced patient outcomes, today announced the start of a randomised controlled clinical trial at St. Georges Hospital, London, UK.

Read more »

DNAe Acquires nanoMR Inc. in a Strategic Move to Own Complete Workflow for Point-Of-Need NGS-Based Blood-To-Result Diagnostic

London, UK and Albuquerque, NM, USA – DNA Electronics Ltd (‘DNAe’), the inventors of semiconductor DNA sequencing technology and developers of a new, revolutionary point-of-need test for blood infections, has on 15 January 2015 completed the acquisition of the entire issued share capital of nanoMR Inc. (‘nanoMR’), an Albuquerque based developer of a novel system for rapid isolation of rare cells in the bloodstream for a total cash consideration of approximately $24 million by way of a merger under the laws of Delaware, USA.

Read more »

NovaBiotics Raises £5.0 million in a Private Placement from Woodford Investment Management

Aberdeen, UK – NovaBiotics Ltd (“NovaBiotics” or the “Company”), announces that Woodford Investment Management LLP (“Woodford IM”) has invested £5.0 million (gross) in a private placement.

Read more »

Imperial Innovations leads £18 million Series B funding round in Veryan

London, UK - Imperial Innovations (AIM: IVO, “Innovations” or ‘The Group’) has led a £18m series B funding round in Veryan Holdings Limited (“Veryan” or “the Company”) alongside co-investors Invesco Asset Management, Seroba Kernel and Seven Mile.  Innovations has committed up to £8.4m to the round and following this new investment, will hold a 47.8% stake in the issued share capital of Veryan (following the conversion of loan stock).

Read more »

Solvanix launched with start-up investment from the MRCF

Sydney, Australia - Solvanix Pty Ltd, an early stage biotechnology company with a novel technology for improving stability and reducing the aggregation of fully human antibodies, developed by the Garvan Institute of Medical Research, was launched today with start-up financing from Australia’s Medical Research Commercialisation Fund (MRCF).

Read more »

Clinigen Group: Half Year Trading Update

Burton-on-Trent, UK –  Clinigen Group plc (‘Clinigen’ or the ‘Group’, AIM: CLIN), the specialty global pharmaceutical company, today provides a half year update for the six months ended
31 December 2014.

Read more »

Prosensa Announces Shareholder Approval of Certain Matters Relating to the BioMarin Tender Offer

Leiden, The Netherlands - Prosensa Holding N.V. (NASDAQ: RNA), the biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, announced that during an extraordinary general meeting of shareholders held today, Prosensa obtained shareholder approval for certain matters relating to the previously disclosed tender offer by BioMarin to purchase all of the outstanding shares of Prosensa.

Read more »

Intercept Provides 2014 Year-End Update and Planned 2015 Milestones

NEW YORK – Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), today provided a clinical update on obeticholic acid (OCA), a novel bile acid analog and first-in-class agonist of the farnesoid X receptor (FXR), as well as planned 2015 milestones and other general business updates. OCA is currently being developed for the treatment of several chronic liver diseases, including primary biliary cirrhosis (PBC), nonalcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC).

Read more »

MISSION appoints Anker Lundemose as Chief Executive Officer

Cambridge, UK – MISSION Therapeutics, a company focused on the discovery and development of modulators of the deubiquitylating (DUB) enzyme family for the treatment of cancer and other diseases, announces the appointment of Dr Anker Lundemose MD PhD as Chief Executive Officer.

Read more »

Seventure Invests EUR 1 M (USD 1.25 M) in First Investment Round for MaaT Pharma

Paris, France – Seventure Partners, one of Europe’s leaders in financing innovation, announces today its investment in MaaT Pharma™, a newly founded French microbiome company. Seventure Partners’ is the first investor in MaaT Pharma™ with a €1 million investment, and has committed to investing a further €1 million on achievement of scientific milestones.

Read more »

Polyphor develops the elastase inhibitor POL6014 for rare lung diseases using PARI Pharma’s eFlow® Technology inhalation device

Allschwil, Switzerland  Polyphor Ltd, a privately held pharmaceutical company specialized in the discovery and development of macrocycle drugs, today announced the signing of a licensing agreement with PARI Pharma, Starnberg, Germany, to use the eFlow® Technology nebulizer for the administration of POL6014, a highly potent and selective inhibitor of neutrophil elastase.

Read more »

Clinical Network Services (CNS) Establishes US Operations

Brisbane, Australia - Clinical Network Services (CNS), an integrated product development company based in Australia, New Zealand and the UK providing comprehensive services in the planning, implementation and delivery of preclinical, Phase 1 and 2 trials, today announced that it has established a new office in the USA under the name “Clinical Network Services USA Inc“. At the same time CNS appointed Megan Hill as the Business Development Manager in the USA.

Read more »

MerLion’s finafloxacin shows positive phase 2 results in complicated urinary tract infections

Singapore - MerLion Pharmaceuticals (“MerLion”), a biopharmaceutical company based in Singapore and Berlin, today announced positive results from a phase 2 trial with finafloxacin, conducted in Europe, treating patients hospitalized with complicated urinary tract infections (cUTI), including a high proportion with pyelonephritis.

Read more »

NetScientific teams up with KU Leuven on research programmes in early cancer detection, epigenomic analysis and fiber-optics diagnostics

NetScientific (AIM: NSCI), the biomedical and healthcare technology group, today announced that it has entered into three research programmes with KU Leuven in Belgium.

Read more »

NetScientific announces investment in DName-iT bringing important improvements to diagnostic Next Generation Sequencing

NetScientific (AIM:NSCI), the biomedical and healthcare technology group, today announced its investment in DName-iT NV (“DName-iT”) a spin-out from KU Leuven in Belgium

Read more »

Nanobiotix 2014 Review, 2015 Anticipated Milestones and Financial Calendar

Paris, France - NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, provides its activities and achievements during 2014 and an overview of anticipated 2015 events including the financial calendar. The Company made major clinical and financial progress, including broadening of indications and strategic plans across Europe, Asia and the US.

Read more »

Five New Clients Engage Instinctif Partners Life Sciences Team

London, Manchester, Munich, New York, Sydney, Melbourne: In the final quarter of 2014, the Life Sciences team of international business communications consultancy, Instinctif Partners, secured five new projects.

Read more »

AmpliPhi Provides Shareholder Update

Richmond, VA, USA, Ljubljana, Slovenia, and Sydney, Australia ― AmpliPhi BioSciences Corporation (OTCQB: APHB), the global leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, provided an update to shareholders during a teleconference on January 5, 2015. The update confirmed the Company is on track to enter human clinical trials in the second half of 2015 with an optimized bacteriophage product targeting multi-drug resistant Staphylococcus aureus. The Company further reported it is preparing for an up-listing to a major stock exchange.

Read more »